2008 0.0 $ 0.2 $ 0.3 $ 1.5 $ 3.5 $ 20.6 $ 13.0 $ 49.9 $ 41.9 $ 131.1 $ 0.3 $ 2.1 $ 2.8 $ 12.9 $ 31.0 $ 179.9 $ 113.8 $ 435.6 $ 365.7 $ 1,144.1 $

2009 0.1 $ 0.3 $ 0.5 $ 2.1 $ 5.0 $ 29.0 $ 18.3 $ 70.2 $ 58.9 $ 184.4 $ 0.4 $ 3.0 $ 3.9 $ 18.2 $ 43.6 $ 253.1 $ 160.1 $ 612.7 $ 514.5 $ 1,609.5 $

2010 0.1 $ 0.4 $ 0.6 $ 2.7 $ 6.5 $ 37.5 $ 23.7 $ 90.9 $ 76.3 $ 238.7 $ 0.6 $ 3.8 $ 5.1 $ 23.5 $ 56.4 $ 327.5 $ 207.2 $ 792.9 $ 665.8 $ 2,082.8 $

2011 0.1 $ 0.5 $ 0.7 $ 3.3 $ 7.9 $ 46.1 $ 29.1 $ 111.5 $ 93.7 $ 293.0 $ 0.7 $ 4.7 $ 6.3 $ 28.9 $ 69.2 $ 402.1 $ 254.3 $ 973.4 $ 817.3 $ 2,556.9 $

2012 0.1 $ 0.6 $ 0.9 $ 3.9 $ 9.4 $ 49.7 $ 31.4 $ 120.4 $ 101.1 $ 317.5 $ 0.8 $ 5.6 $ 7.4 $ 34.2 $ 81.9 $ 433.9 $ 274.4 $ 1,050.4 $ 882.0 $ 2,770.6 $

2013 0.1 $ 0.7 $ 1.0 $ 4.5 $ 10.8 $ 51.6 $ 32.6 $ 124.9 $ 104.9 $ 331.3 $ 0.9 $ 6.4 $ 8.6 $ 39.4 $ 94.5 $ 450.4 $ 284.9 $ 1,090.3 $ 915.5 $ 2,890.9 $

2014 0.1 $ 0.8 $ 1.1 $ 5.1 $ 12.2 $ 52.6 $ 33.3 $ 127.4 $ 107.0 $ 339.6 $ 1.1 $ 7.3 $ 9.7 $ 44.6 $ 106.7 $ 459.2 $ 290.4 $ 1,111.6 $ 933.4 $ 2,963.9 $

2015 0.1 $ 0.9 $ 1.2 $ 5.4 $ 12.8 $ 53.1 $ 33.6 $ 128.5 $ 107.9 $ 343.5 $ 1.1 $ 7.6 $ 10.1 $ 46.7 $ 111.9 $ 463.4 $ 293.1 $ 1,121.9 $ 942.0 $ 2,997.9 $

2016 0.1 $ 0.9 $ 1.2 $ 5.5 $ 13.1 $ 53.2 $ 33.7 $ 128.9 $ 108.2 $ 344.9 $ 1.1 $ 7.8 $ 10.4 $ 47.8 $ 114.4 $ 464.7 $ 293.9 $ 1,125.0 $ 944.7 $ 3,009.8 $

2017 0.1 $ 0.9 $ 1.2 $ 5.5 $ 13.2 $ 53.2 $ 33.6 $ 128.7 $ 108.1 $ 344.6 $ 1.2 $ 7.9 $ 10.5 $ 48.3 $ 115.6 $ 464.0 $ 293.5 $ 1,123.4 $ 943.2 $ 3,007.5 $

2018 0.1 $ 0.9 $ 1.2 $ 5.5 $ 13.3 $ 52.9 $ 33.5 $ 128.1 $ 107.6 $ 343.2 $ 1.2 $ 7.9 $ 10.5 $ 48.4 $ 115.9 $ 461.9 $ 292.2 $ 1,118.2 $ 939.0 $ 2,995.2 $

2019 0.1 $ 0.9 $ 1.2 $ 5.5 $ 13.3 $ 52.6 $ 33.2 $ 127.3 $ 106.9 $ 341.0 $ 1.2 $ 7.9 $ 10.5 $ 48.3 $ 115.8 $ 458.8 $ 290.2 $ 1,110.6 $ 932.6 $ 2,975.7 $

2020 0.1 $ 0.9 $ 1.2 $ 5.5 $ 13.2 $ 52.1 $ 33.0 $ 126.2 $ 105.9 $ 338.1 $ 1.2 $ 7.8 $ 10.4 $ 48.1 $ 115.2 $ 454.8 $ 287.7 $ 1,101.1 $ 924.6 $ 2,951.0 $

2021 0.1 $ 0.9 $ 1.2 $ 5.5 $ 13.1 $ 51.6 $ 32.6 $ 124.9 $ 104.9 $ 334.9 $ 1.1 $ 7.8 $ 10.4 $ 47.8 $ 114.4 $ 450.3 $ 284.9 $ 1,090.2 $ 915.4 $ 2,922.4 $

2022 0.1 $ 0.9 $ 1.2 $ 5.4 $ 13.0 $ 51.0 $ 32.3 $ 123.5 $ 103.7 $ 331.2 $ 1.1 $ 7.7 $ 10.3 $ 47.3 $ 113.4 $ 445.4 $ 281.7 $ 1,078.2 $ 905.4 $ 2,890.6 $

2023 0.1 $ 0.9 $ 1.2 $ 5.4 $ 12.9 $ 50.4 $ 31.9 $ 122.1 $ 102.5 $ 327.3 $ 1.1 $ 7.6 $ 10.2 $ 46.9 $ 112.3 $ 440.1 $ 278.4 $ 1,065.4 $ 894.6 $ 2,856.5 $

2024 0.1 $ 0.9 $ 1.2 $ 5.3 $ 12.7 $ 49.8 $ 31.5 $ 120.5 $ 101.2 $ 323.2 $ 1.1 $ 7.6 $ 10.1 $ 46.3 $ 111.0 $ 434.5 $ 274.8 $ 1,051.9 $ 883.2 $ 2,820.5 $

2025 0.1 $ 0.9 $ 1.1 $ 5.2 $ 12.6 $ 49.1 $ 31.1 $ 118.9 $ 99.9 $ 318.9 $ 1.1 $ 7.5 $ 9.9 $ 45.8 $ 109.7 $ 428.7 $ 271.2 $ 1,037.9 $ 871.5 $ 2,783.2 $

2026 0.1 $ 0.8 $ 1.1 $ 5.2 $ 12.4 $ 48.4 $ 30.6 $ 117.3 $ 98.5 $ 314.5 $ 1.1 $ 7.4 $ 9.8 $ 45.2 $ 108.2 $ 422.8 $ 267.4 $ 1,023.5 $ 859.4 $ 2,744.8 $

2027 0.1 $ 0.8 $ 1.1 $ 5.1 $ 12.2 $ 47.7 $ 30.2 $ 115.6 $ 97.1 $ 310.0 $ 1.1 $ 7.3 $ 9.7 $ 44.6 $ 106.8 $ 416.7 $ 263.6 $ 1,008.9 $ 847.1 $ 2,705.7 $

Total 2.3 $ 15.4 $ 20.5 $ 94.5 $ 226.3 $ 970.4 $ 613.8 $ 2,349.3 $ 1,972.7 $ 6,265.2 $ 19.8 $ 134.3 $ 178.9 $ 824.5 $ 1,974.8 $ 8,469.2 $ 5,357.0 $ 20,503.4 $ 17,215.9 $ 54,677.8 $

Ann. 0.1 $ 0.9 $ 1.2 $ 5.4 $ 13.0 $ 55.7 $ 35.3 $ 134.9 $ 113.3 $ 359.8 $ 1.1 $ 7.7 $ 10.3 $ 47.3 $ 113.4 $ 486.4 $ 307.6 $ 1,177.5 $ 988.7 $ 3,140.0 $

Notes:

Source: Derived from Exhibits F. 16a and F. 16b. Exhibit F. 16f Mean Present Value of Benefits Yearly Projections, WTP for Lymphoma as Basis for Non Fatal Cases, at 3% Discount Rate, by System Size ( All Systems)

17% Estimate of PAR Present values in millions of 2000 dollars. Estimates are discounted to 2003.

Detail may not add exactly to totals due to independent rounding. 2% Estimate of PAR Ann. = value of total annualized at discount rate.

Economic Analysis for the Stage 2 DBPR July 2003 TTHM  IDSE Sensitivity Analysis 2 Year < 100 101 500 501 1K 1,001 3,3K 3,301 10K 10,001 50K 50,001 100K 100,001 1M > 1M Total < 100 101 500 501 1K 1,001 3,3K 3,301 10K 10,001 50K 50,001 100K 100,001 1M > 1M Total 2003  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $

2004  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $

2005  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $

2006 0.0 $ 0.1 $ 0.1 $ 0.3 $ 0.8 $ 4.8 $ 3.0 $ 11.6 $ 9.8 $ 30.6 $ 0.1 $ 0.5 $ 0.7 $ 3.0 $ 7.2 $ 41.9 $ 26.5 $ 101.6 $ 85.3 $ 266.8 $

2007 0.0 $ 0.1 $ 0.2 $ 0.8 $ 1.9 $ 10.8 $ 6.8 $ 26.2 $ 22.0 $ 68.8 $ 0.2 $ 1.1 $ 1.5 $ 6.8 $ 16.3 $ 94.4 $ 59.7 $ 228.6 $ 192.0 $ 600.5 $

2008 0.0 $ 0.2 $ 0.3 $ 1.2 $ 2.9 $ 17.0 $ 10.8 $ 41.3 $ 34.6 $ 108.4 $ 0.3 $ 1.7 $ 2.3 $ 10.7 $ 25.6 $ 148.7 $ 94.1 $ 360.0 $ 302.3 $ 945.7 $

2009 0.0 $ 0.3 $ 0.4 $ 1.7 $ 4.0 $ 23.1 $ 14.6 $ 55.9 $ 46.9 $ 146.7 $ 0.3 $ 2.4 $ 3.1 $ 14.5 $ 34.7 $ 201.4 $ 127.4 $ 487.5 $ 409.3 $ 1,280.6 $

2010 0.0 $ 0.3 $ 0.4 $ 2.1 $ 4.9 $ 28.7 $ 18.2 $ 69.6 $ 58.4 $ 182.8 $ 0.4 $ 2.9 $ 3.9 $ 18.0 $ 43.2 $ 250.9 $ 158.7 $ 607.3 $ 509.9 $ 1,595.2 $

2011 0.1 $ 0.4 $ 0.5 $ 2.4 $ 5.8 $ 34.0 $ 21.5 $ 82.2 $ 69.0 $ 216.0 $ 0.5 $ 3.5 $ 4.6 $ 21.3 $ 51.0 $ 296.4 $ 187.5 $ 717.7 $ 602.6 $ 1,885.1 $

2012 0.1 $ 0.5 $ 0.6 $ 2.8 $ 6.7 $ 35.3 $ 22.3 $ 85.4 $ 71.7 $ 225.3 $ 0.6 $ 4.0 $ 5.3 $ 24.3 $ 58.1 $ 307.9 $ 194.8 $ 745.5 $ 625.9 $ 1,966.3 $

2013 0.1 $ 0.5 $ 0.7 $ 3.1 $ 7.4 $ 35.3 $ 22.3 $ 85.4 $ 71.7 $ 226.3 $ 0.6 $ 4.4 $ 5.8 $ 26.9 $ 64.5 $ 307.7 $ 194.6 $ 744.9 $ 625.5 $ 1,975.0 $

2014 0.1 $ 0.5 $ 0.7 $ 3.4 $ 8.0 $ 34.6 $ 21.9 $ 83.8 $ 70.3 $ 223.3 $ 0.7 $ 4.8 $ 6.4 $ 29.3 $ 70.2 $ 302.0 $ 191.0 $ 731.0 $ 613.8 $ 1,949.2 $

2015 0.1 $ 0.6 $ 0.7 $ 3.4 $ 8.1 $ 33.6 $ 21.3 $ 81.4 $ 68.3 $ 217.5 $ 0.7 $ 4.8 $ 6.4 $ 29.6 $ 70.8 $ 293.4 $ 185.6 $ 710.2 $ 596.3 $ 1,897.8 $

2016 0.1 $ 0.5 $ 0.7 $ 3.3 $ 8.0 $ 32.4 $ 20.5 $ 78.6 $ 66.0 $ 210.2 $ 0.7 $ 4.7 $ 6.3 $ 29.1 $ 69.7 $ 283.2 $ 179.1 $ 685.6 $ 575.7 $ 1,834.2 $

2017 0.1 $ 0.5 $ 0.7 $ 3.2 $ 7.8 $ 31.2 $ 19.7 $ 75.5 $ 63.4 $ 202.1 $ 0.7 $ 4.6 $ 6.1 $ 28.3 $ 67.8 $ 272.2 $ 172.2 $ 659.0 $ 553.3 $ 1,764.2 $

2018 0.1 $ 0.5 $ 0.7 $ 3.1 $ 7.5 $ 29.9 $ 18.9 $ 72.4 $ 60.8 $ 193.8 $ 0.7 $ 4.5 $ 5.9 $ 27.3 $ 65.5 $ 260.8 $ 165.0 $ 631.5 $ 530.2 $ 1,691.3 $

2019 0.1 $ 0.5 $ 0.7 $ 3.0 $ 7.2 $ 28.6 $ 18.1 $ 69.2 $ 58.1 $ 185.3 $ 0.6 $ 4.3 $ 5.7 $ 26.3 $ 62.9 $ 249.4 $ 157.7 $ 603.7 $ 506.9 $ 1,617.5 $

2020 0.1 $ 0.5 $ 0.6 $ 2.9 $ 6.9 $ 27.3 $ 17.2 $ 66.0 $ 55.4 $ 176.9 $ 0.6 $ 4.1 $ 5.5 $ 25.2 $ 60.3 $ 238.0 $ 150.5 $ 576.2 $ 483.8 $ 1,544.1 $

2021 0.1 $ 0.4 $ 0.6 $ 2.8 $ 6.6 $ 26.0 $ 16.4 $ 62.9 $ 52.8 $ 168.7 $ 0.6 $ 3.9 $ 5.2 $ 24.1 $ 57.6 $ 226.8 $ 143.5 $ 549.1 $ 461.1 $ 1,472.0 $

2022 0.1 $ 0.4 $ 0.6 $ 2.6 $ 6.3 $ 24.7 $ 15.7 $ 59.9 $ 50.3 $ 160.6 $ 0.6 $ 3.7 $ 5.0 $ 23.0 $ 55.0 $ 215.9 $ 136.6 $ 522.8 $ 439.0 $ 1,401.5 $

2023 0.1 $ 0.4 $ 0.5 $ 2.5 $ 6.0 $ 23.5 $ 14.9 $ 57.0 $ 47.8 $ 152.8 $ 0.5 $ 3.6 $ 4.7 $ 21.9 $ 52.4 $ 205.4 $ 129.9 $ 497.3 $ 417.5 $ 1,333.2 $

2024 0.1 $ 0.4 $ 0.5 $ 2.4 $ 5.7 $ 22.4 $ 14.1 $ 54.2 $ 45.5 $ 145.2 $ 0.5 $ 3.4 $ 4.5 $ 20.8 $ 49.9 $ 195.2 $ 123.5 $ 472.6 $ 396.8 $ 1,267.2 $

2025 0.1 $ 0.4 $ 0.5 $ 2.3 $ 5.4 $ 21.2 $ 13.4 $ 51.4 $ 43.2 $ 137.9 $ 0.5 $ 3.2 $ 4.3 $ 19.8 $ 47.4 $ 185.4 $ 117.3 $ 448.9 $ 376.9 $ 1,203.7 $

2026 0.1 $ 0.4 $ 0.5 $ 2.2 $ 5.2 $ 20.2 $ 12.8 $ 48.8 $ 41.0 $ 130.9 $ 0.5 $ 3.1 $ 4.1 $ 18.8 $ 45.1 $ 176.0 $ 111.3 $ 426.1 $ 357.8 $ 1,142.7 $

2027 0.0 $ 0.3 $ 0.4 $ 2.0 $ 4.9 $ 19.1 $ 12.1 $ 46.3 $ 38.9 $ 124.2 $ 0.4 $ 2.9 $ 3.9 $ 17.9 $ 42.8 $ 167.0 $ 105.6 $ 404.3 $ 339.5 $ 1,084.3 $

Total 1.3 $ 8.7 $ 11.6 $ 53.5 $ 128.1 $ 563.8 $ 356.6 $ 1,364.8 $ 1,146.0 $ 3,634.4 $ 11.2 $ 76.1 $ 101.3 $ 466.7 $ 1,118.0 $ 4,920.1 $ 3,112.1 $ 11,911.2 $ 10,001.4 $ 31,718.2 $

Ann. 0.1 $ 0.7 $ 1.0 $ 4.6 $ 11.0 $ 48.4 $ 30.6 $ 117.1 $ 98.3 $ 311.9 $ 1.0 $ 6.5 $ 8.7 $ 40.1 $ 95.9 $ 422.2 $ 267.0 $ 1,022.1 $ 858.2 $ 2,721.8 $

Notes:

Source: Derived from Exhibits F. 16a and F. 16b. Present values in millions of 2000 dollars. Estimates are discounted to 2003.

Detail may not add exactly to totals due to independent rounding. 2% Estimate of PAR Exhibit F. 16g Mean Present Value of Benefits Yearly Projections, WTP for Lymphoma as Basis for Non Fatal Cases, at 7% Discount Rate, by System Size ( All Systems)

17% Estimate of PAR Ann. = value of total annualized at discount rate.

Economic Analysis for the Stage 2 DBPR July 2003 Section F. 17 Model Outputs  IDSE Sensitivity Analysis 2 TTHM as Indicator Bronchitis for Non Fatal Cases Economic Analysis for the Stage 2 DBPR July 2003 TTHM  IDSE Sensitivity Analysis 2 Lower ( 5th % tile) Upper ( 95th % tile) Lower ( 5th % tile) Upper ( 95th % tile) Lower ( 5th % tile) Upper ( 95th % tile) Lower ( 5th % tile) Upper ( 95th % tile) Lower ( 5th % tile) Upper ( 95th % tile) Lower ( 5th % tile) Upper ( 95th % tile)

2003  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $

2004  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $

2005  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $

2006 13.5 $ 11.7 $ 2.2 $ 30.6 $ 3.9 $ 3.6 $ 1.8 $ 7.1 $ 17.3 $ 15.3 $ 4.0 $ 37.7 $ 117.5 $ 102.3 $ 19.6 $ 266.9 $ 33.8 $ 31.1 $ 15.3 $ 61.8 $ 151.2 $ 133.4 $ 34.9 $ 328.7 $

2007 32.4 $ 28.2 $ 5.4 $ 73.7 $ 9.3 $ 8.6 $ 4.2 $ 17.0 $ 41.7 $ 36.8 $ 9.6 $ 90.7 $ 282.9 $ 246.4 $ 47.2 $ 643.0 $ 81.2 $ 74.7 $ 36.7 $ 148.5 $ 364.1 $ 321.1 $ 83.8 $ 791.5 $

2008 54.6 $ 47.6 $ 9.1 $ 124.1 $ 15.7 $ 14.4 $ 7.1 $ 28.6 $ 70.3 $ 62.0 $ 16.2 $ 152.8 $ 476.6 $ 415.1 $ 79.4 $ 1,083.3 $ 136.7 $ 125.8 $ 61.7 $ 249.8 $ 613.3 $ 540.8 $ 141.1 $ 1,333.1 $

2009 79.1 $ 68.9 $ 13.2 $ 179.9 $ 22.7 $ 20.9 $ 10.2 $ 41.4 $ 101.8 $ 89.8 $ 23.4 $ 221.3 $ 690.5 $ 601.4 $ 114.9 $ 1,569.6 $ 197.7 $ 182.0 $ 89.1 $ 361.3 $ 888.2 $ 783.4 $ 204.1 $ 1,930.9 $

2010 105.4 $ 91.8 $ 17.5 $ 239.7 $ 30.1 $ 27.8 $ 13.6 $ 55.1 $ 135.6 $ 119.6 $ 31.1 $ 294.8 $ 920.3 $ 801.5 $ 153.1 $ 2,092.2 $ 263.1 $ 242.4 $ 118.6 $ 480.8 $ 1,183.4 $ 1,043.9 $ 271.7 $ 2,573.0 $

2011 133.3 $ 116.1 $ 22.2 $ 303.1 $ 38.1 $ 35.1 $ 17.2 $ 69.7 $ 171.4 $ 151.2 $ 39.3 $ 372.8 $ 1,163.5 $ 1,013.3 $ 193.4 $ 2,645.5 $ 332.2 $ 306.0 $ 149.8 $ 607.9 $ 1,495.7 $ 1,319.3 $ 343.2 $ 3,253.3 $

2012 148.7 $ 129.5 $ 24.7 $ 338.0 $ 42.4 $ 39.0 $ 19.1 $ 77.6 $ 191.0 $ 168.5 $ 43.8 $ 415.7 $ 1,297.4 $ 1,129.9 $ 215.5 $ 2,950.1 $ 369.8 $ 340.8 $ 166.5 $ 677.4 $ 1,667.2 $ 1,470.7 $ 382.0 $ 3,627.5 $

2013 159.6 $ 139.0 $ 26.5 $ 362.9 $ 45.4 $ 41.9 $ 20.5 $ 83.2 $ 205.0 $ 180.9 $ 47.0 $ 446.1 $ 1,392.9 $ 1,213.0 $ 231.2 $ 3,167.5 $ 396.4 $ 365.4 $ 178.6 $ 725.7 $ 1,789.3 $ 1,578.4 $ 409.8 $ 3,893.2 $

2014 168.3 $ 146.6 $ 27.9 $ 382.8 $ 47.8 $ 44.1 $ 21.6 $ 87.6 $ 216.2 $ 190.7 $ 49.5 $ 470.4 $ 1,469.2 $ 1,279.5 $ 243.7 $ 3,341.2 $ 417.5 $ 384.9 $ 188.2 $ 764.4 $ 1,886.6 $ 1,664.3 $ 431.8 $ 4,105.6 $

2015 175.3 $ 152.7 $ 29.1 $ 398.7 $ 49.7 $ 45.9 $ 22.4 $ 91.1 $ 225.0 $ 198.5 $ 51.4 $ 489.8 $ 1,529.8 $ 1,332.2 $ 253.5 $ 3,479.4 $ 434.0 $ 400.2 $ 195.4 $ 794.9 $ 1,963.8 $ 1,732.4 $ 448.9 $ 4,274.4 $

2016 181.2 $ 157.8 $ 30.0 $ 412.2 $ 51.3 $ 47.3 $ 23.1 $ 94.0 $ 232.5 $ 205.1 $ 53.1 $ 506.2 $ 1,581.5 $ 1,377.2 $ 261.9 $ 3,597.3 $ 448.0 $ 413.1 $ 201.4 $ 820.4 $ 2,029.4 $ 1,790.3 $ 463.3 $ 4,417.6 $

2017 186.5 $ 162.4 $ 30.9 $ 424.2 $ 52.7 $ 48.6 $ 23.7 $ 96.6 $ 239.2 $ 211.0 $ 54.6 $ 520.8 $ 1,627.3 $ 1,417.1 $ 269.3 $ 3,701.7 $ 460.2 $ 424.4 $ 207.0 $ 843.1 $ 2,087.4 $ 1,841.5 $ 476.4 $ 4,544.8 $

2018 191.2 $ 166.5 $ 31.6 $ 435.1 $ 54.0 $ 49.8 $ 24.3 $ 99.0 $ 245.2 $ 216.3 $ 55.9 $ 534.0 $ 1,668.9 $ 1,453.4 $ 276.0 $ 3,796.8 $ 471.2 $ 434.6 $ 211.9 $ 863.7 $ 2,140.1 $ 1,888.0 $ 487.9 $ 4,660.5 $

2019 195.7 $ 170.4 $ 32.3 $ 445.2 $ 55.1 $ 50.9 $ 24.8 $ 101.1 $ 250.8 $ 221.3 $ 57.1 $ 546.3 $ 1,707.6 $ 1,487.0 $ 282.2 $ 3,885.1 $ 481.3 $ 443.9 $ 216.4 $ 882.5 $ 2,188.9 $ 1,930.9 $ 498.7 $ 4,767.6 $

2020 199.8 $ 174.0 $ 33.0 $ 454.7 $ 56.2 $ 51.8 $ 25.3 $ 103.2 $ 256.1 $ 225.9 $ 58.3 $ 557.9 $ 1,744.0 $ 1,518.7 $ 288.1 $ 3,968.3 $ 490.7 $ 452.4 $ 220.5 $ 900.8 $ 2,234.7 $ 1,971.1 $ 508.6 $ 4,869.1 $

2021 203.8 $ 177.5 $ 33.6 $ 463.8 $ 57.2 $ 52.8 $ 25.7 $ 105.1 $ 261.0 $ 230.2 $ 59.4 $ 568.9 $ 1,778.7 $ 1,548.8 $ 293.6 $ 4,047.4 $ 499.6 $ 460.4 $ 224.7 $ 917.3 $ 2,278.2 $ 2,009.2 $ 518.3 $ 4,964.7 $

2022 207.6 $ 180.8 $ 34.2 $ 472.5 $ 58.2 $ 53.6 $ 26.2 $ 107.0 $ 265.8 $ 234.4 $ 60.4 $ 579.4 $ 1,811.9 $ 1,577.7 $ 298.9 $ 4,123.4 $ 508.0 $ 468.2 $ 228.5 $ 933.4 $ 2,319.9 $ 2,045.9 $ 527.4 $ 5,056.8 $

2023 211.3 $ 184.0 $ 34.8 $ 480.9 $ 59.1 $ 54.5 $ 26.6 $ 108.7 $ 270.4 $ 238.5 $ 61.4 $ 589.6 $ 1,844.0 $ 1,605.7 $ 304.0 $ 4,196.8 $ 516.1 $ 475.7 $ 232.1 $ 948.9 $ 2,360.1 $ 2,081.4 $ 536.0 $ 5,145.7 $

2024 214.9 $ 187.1 $ 35.4 $ 489.1 $ 60.0 $ 55.4 $ 27.0 $ 110.4 $ 274.9 $ 242.4 $ 62.4 $ 599.4 $ 1,875.3 $ 1,632.8 $ 308.9 $ 4,268.2 $ 523.9 $ 483.1 $ 235.5 $ 963.1 $ 2,399.2 $ 2,115.9 $ 544.4 $ 5,231.3 $

2025 218.4 $ 190.1 $ 36.0 $ 497.1 $ 60.9 $ 56.1 $ 27.4 $ 111.9 $ 279.3 $ 246.3 $ 63.4 $ 609.0 $ 1,905.8 $ 1,659.3 $ 313.8 $ 4,338.0 $ 531.4 $ 490.0 $ 239.2 $ 976.8 $ 2,437.2 $ 2,149.3 $ 553.0 $ 5,314.8 $

2026 221.8 $ 193.1 $ 36.5 $ 504.9 $ 61.7 $ 56.9 $ 27.8 $ 113.5 $ 283.5 $ 250.1 $ 64.3 $ 618.4 $ 1,935.7 $ 1,685.3 $ 318.5 $ 4,406.4 $ 538.8 $ 497.0 $ 242.6 $ 990.5 $ 2,474.5 $ 2,182.3 $ 561.1 $ 5,396.9 $

2027 225.2 $ 196.0 $ 37.0 $ 512.6 $ 62.6 $ 57.7 $ 28.1 $ 115.0 $ 287.7 $ 253.8 $ 65.2 $ 627.7 $ 1,965.2 $ 1,711.0 $ 323.1 $ 4,473.8 $ 546.0 $ 503.9 $ 245.6 $ 1,004.0 $ 2,511.2 $ 2,214.9 $ 568.7 $ 5,477.8 $

Total 3,527.6 $ 3,071.8 $ 583.2 $ 8,025.7 $ 994.3 $ 916.6 $ 447.5 $ 1,823.8 $ 4,521.9 $ 3,988.5 $ 1,030.7 $ 9,849.4 $ 30,786.3 $ 26,808.6 $ 5,089.8 $ 70,042.1 $ 8,677.4 $ 7,999.8 $ 3,905.2 $ 15,916.8 $ 39,463.8 $ 34,808.4 $ 8,995.0 $ 85,958.8 $

Notes: All values in millions of year 2000 dollars.

Detail may not add exactly to totals due to independent rounding.

Source: Derived from Exhibits F. 1f, E. 24b, and E. 24e. Exhibit F. 17a Projections of Yearly Benefits, WTP for Bronchitis as Basis for Non Fatal Cases Mean Value Median Value 90 Percent Confidence Bound Mean Value Median Value 90 Percent Confidence Bound Median Value 90 Percent Confidence Bound Mean Value Median Value Mean Value Median Value 90 Percent Confidence Bound 90 Percent Confidence Bound Non Fatal Cases Total 2% Estimate of PAR 17% Estimate of PAR ( All Surface Water Systems)

Total Fatal Cases Fatal Cases Year Mean Value Median Value 90 Percent Confidence Bound Non Fatal Cases Mean Value Economic Analysis for the Stage 2 DBPR July 2003 TTHM  IDSE Sensitivity Analysis 2 Lower ( 5th % tile) Upper ( 95th % tile) Lower ( 5th % tile) Upper ( 95th % tile) Lower ( 5th % tile) Upper ( 95th % tile) Lower ( 5th % tile) Upper ( 95th % tile) Lower ( 5th % tile) Upper ( 95th % tile) Lower ( 5th % tile) Upper ( 95th % tile)

2003  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $

2004  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $

2005  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $

2006 0.7 $ 0.7 $ 0.1 $ 1.7 $ 0.2 $ 0.2 $ 0.1 $ 0.4 $ 1.0 $ 0.9 $ 0.2 $ 2.1 $ 6.5 $ 5.7 $ 1.1 $ 14.9 $ 1.9 $ 1.7 $ 0.9 $ 3.4 $ 8.4 $ 7.4 $ 1.9 $ 18.3 $

2007 1.8 $ 1.6 $ 0.3 $ 4.1 $ 0.5 $ 0.5 $ 0.2 $ 0.9 $ 2.3 $ 2.0 $ 0.5 $ 5.1 $ 15.8 $ 13.7 $ 2.6 $ 35.8 $ 4.5 $ 4.2 $ 2.0 $ 8.3 $ 20.3 $ 17.9 $ 4.7 $ 44.1 $

2008 3.0 $ 2.6 $ 0.5 $ 6.9 $ 0.9 $ 0.8 $ 0.4 $ 1.6 $ 3.9 $ 3.5 $ 0.9 $ 8.5 $ 26.5 $ 23.1 $ 4.4 $ 60.3 $ 7.6 $ 7.0 $ 3.4 $ 13.9 $ 34.2 $ 30.1 $ 7.9 $ 74.3 $

2009 4.4 $ 3.8 $ 0.7 $ 10.0 $ 1.3 $ 1.2 $ 0.6 $ 2.3 $ 5.7 $ 5.0 $ 1.3 $ 12.3 $ 38.5 $ 33.5 $ 6.4 $ 87.4 $ 11.0 $ 10.1 $ 5.0 $ 20.1 $ 49.5 $ 43.6 $ 11.4 $ 107.5 $

2010 5.9 $ 5.1 $ 1.0 $ 13.4 $ 1.7 $ 1.5 $ 0.8 $ 3.1 $ 7.6 $ 6.7 $ 1.7 $ 16.4 $ 51.3 $ 44.6 $ 8.5 $ 116.5 $ 14.7 $ 13.5 $ 6.6 $ 26.8 $ 65.9 $ 58.1 $ 15.1 $ 143.3 $

2011 7.4 $ 6.5 $ 1.2 $ 16.9 $ 2.1 $ 2.0 $ 1.0 $ 3.9 $ 9.5 $ 8.4 $ 2.2 $ 20.8 $ 64.8 $ 56.4 $ 10.8 $ 147.3 $ 18.5 $ 17.0 $ 8.3 $ 33.9 $ 83.3 $ 73.5 $ 19.1 $ 181.2 $

2012 8.4 $ 7.3 $ 1.4 $ 19.1 $ 2.4 $ 2.2 $ 1.1 $ 4.4 $ 10.8 $ 9.5 $ 2.5 $ 23.5 $ 73.4 $ 63.9 $ 12.2 $ 166.8 $ 20.9 $ 19.3 $ 9.4 $ 38.3 $ 94.3 $ 83.2 $ 21.6 $ 205.1 $

2013 9.2 $ 8.0 $ 1.5 $ 20.9 $ 2.6 $ 2.4 $ 1.2 $ 4.8 $ 11.8 $ 10.4 $ 2.7 $ 25.7 $ 80.2 $ 69.9 $ 13.3 $ 182.5 $ 22.8 $ 21.0 $ 10.3 $ 41.8 $ 103.1 $ 90.9 $ 23.6 $ 224.3 $

2014 9.9 $ 8.6 $ 1.6 $ 22.5 $ 2.8 $ 2.6 $ 1.3 $ 5.1 $ 12.7 $ 11.2 $ 2.9 $ 27.6 $ 86.3 $ 75.2 $ 14.3 $ 196.3 $ 24.5 $ 22.6 $ 11.1 $ 44.9 $ 110.8 $ 97.8 $ 25.4 $ 241.2 $

2015 10.4 $ 9.0 $ 1.7 $ 23.6 $ 2.9 $ 2.7 $ 1.3 $ 5.4 $ 13.3 $ 11.7 $ 3.0 $ 29.0 $ 90.5 $ 78.9 $ 15.0 $ 205.9 $ 25.7 $ 23.7 $ 11.6 $ 47.1 $ 116.2 $ 102.5 $ 26.6 $ 253.0 $

2016 10.8 $ 9.4 $ 1.8 $ 24.5 $ 3.1 $ 2.8 $ 1.4 $ 5.6 $ 13.8 $ 12.2 $ 3.2 $ 30.1 $ 94.0 $ 81.8 $ 15.6 $ 213.8 $ 26.6 $ 24.5 $ 12.0 $ 48.8 $ 120.6 $ 106.4 $ 27.5 $ 262.5 $

2017 11.1 $ 9.7 $ 1.8 $ 25.3 $ 3.1 $ 2.9 $ 1.4 $ 5.8 $ 14.2 $ 12.6 $ 3.3 $ 31.0 $ 96.9 $ 84.4 $ 16.0 $ 220.5 $ 27.4 $ 25.3 $ 12.3 $ 50.2 $ 124.3 $ 109.7 $ 28.4 $ 270.7 $

2018 11.4 $ 9.9 $ 1.9 $ 26.0 $ 3.2 $ 3.0 $ 1.4 $ 5.9 $ 14.6 $ 12.9 $ 3.3 $ 31.9 $ 99.6 $ 86.7 $ 16.5 $ 226.5 $ 28.1 $ 25.9 $ 12.6 $ 51.5 $ 127.7 $ 112.6 $ 29.1 $ 278.1 $

2019 11.7 $ 10.2 $ 1.9 $ 26.6 $ 3.3 $ 3.0 $ 1.5 $ 6.0 $ 15.0 $ 13.2 $ 3.4 $ 32.6 $ 102.0 $ 88.8 $ 16.9 $ 232.1 $ 28.7 $ 26.5 $ 12.9 $ 52.7 $ 130.7 $ 115.3 $ 29.8 $ 284.8 $

2020 11.9 $ 10.4 $ 2.0 $ 27.2 $ 3.4 $ 3.1 $ 1.5 $ 6.2 $ 15.3 $ 13.5 $ 3.5 $ 33.4 $ 104.3 $ 90.8 $ 17.2 $ 237.2 $ 29.3 $ 27.0 $ 13.2 $ 53.9 $ 133.6 $ 117.8 $ 30.4 $ 291.1 $

2021 12.2 $ 10.6 $ 2.0 $ 27.7 $ 3.4 $ 3.2 $ 1.5 $ 6.3 $ 15.6 $ 13.8 $ 3.6 $ 34.0 $ 106.4 $ 92.6 $ 17.6 $ 242.1 $ 29.9 $ 27.5 $ 13.4 $ 54.9 $ 136.3 $ 120.2 $ 31.0 $ 297.0 $

2022 12.4 $ 10.8 $ 2.0 $ 28.3 $ 3.5 $ 3.2 $ 1.6 $ 6.4 $ 15.9 $ 14.0 $ 3.6 $ 34.7 $ 108.4 $ 94.4 $ 17.9 $ 246.8 $ 30.4 $ 28.0 $ 13.7 $ 55.9 $ 138.8 $ 122.4 $ 31.6 $ 302.6 $

2023 12.6 $ 11.0 $ 2.1 $ 28.8 $ 3.5 $ 3.3 $ 1.6 $ 6.5 $ 16.2 $ 14.3 $ 3.7 $ 35.3 $ 110.4 $ 96.1 $ 18.2 $ 251.3 $ 30.9 $ 28.5 $ 13.9 $ 56.8 $ 141.3 $ 124.6 $ 32.1 $ 308.1 $

2024 12.9 $ 11.2 $ 2.1 $ 29.3 $ 3.6 $ 3.3 $ 1.6 $ 6.6 $ 16.5 $ 14.5 $ 3.7 $ 35.9 $ 112.3 $ 97.8 $ 18.5 $ 255.6 $ 31.4 $ 28.9 $ 14.1 $ 57.7 $ 143.7 $ 126.7 $ 32.6 $ 313.3 $

2025 13.1 $ 11.4 $ 2.2 $ 29.8 $ 3.6 $ 3.4 $ 1.6 $ 6.7 $ 16.7 $ 14.8 $ 3.8 $ 36.5 $ 114.2 $ 99.4 $ 18.8 $ 259.9 $ 31.8 $ 29.3 $ 14.3 $ 58.5 $ 146.0 $ 128.7 $ 33.1 $ 318.4 $

2026 13.3 $ 11.6 $ 2.2 $ 30.3 $ 3.7 $ 3.4 $ 1.7 $ 6.8 $ 17.0 $ 15.0 $ 3.9 $ 37.1 $ 116.0 $ 101.0 $ 19.1 $ 264.0 $ 32.3 $ 29.8 $ 14.5 $ 59.3 $ 148.3 $ 130.8 $ 33.6 $ 323.4 $

2027 13.5 $ 11.7 $ 2.2 $ 30.7 $ 3.7 $ 3.5 $ 1.7 $ 6.9 $ 17.2 $ 15.2 $ 3.9 $ 37.6 $ 117.8 $ 102.5 $ 19.4 $ 268.1 $ 32.7 $ 30.2 $ 14.7 $ 60.2 $ 150.5 $ 132.7 $ 34.1 $ 328.3 $

Total 208.1 $ 181.2 $ 34.4 $ 473.4 $ 58.6 $ 54.1 $ 26.4 $ 107.6 $ 266.7 $ 235.3 $ 60.8 $ 581.0 $ 1,816.0 $ 1,581.4 $ 300.2 $ 4,131.6 $ 511.8 $ 471.8 $ 230.3 $ 938.7 $ 2,327.8 $ 2,053.2 $ 530.5 $ 5,070.4 $

Notes: All values in millions of year 2000 dollars.

Detail may not add exactly to totals due to independent rounding.

Source: Derived from Exhibits F. 1f, E. 24c, and E. 24f. 90 Percent Confidence Bound Fatal Cases Fatal Cases Non Fatal Cases Total Mean Value Median Value 90 Percent Confidence Bound Median Value Mean Value Median Value 90 Percent Confidence Bound Mean Value Median Value Mean Value 2% Estimate of PAR Exhibit F. 17b Projections of Yearly Benefits, WTP for Bronchitis as Basis for Non Fatal Cases ( All Ground Water Systems)

Total Year 17% Estimate of PAR 90 Percent Confidence Bound Mean Value 90 Percent Confidence Bound 90 Percent Confidence Bound Non Fatal Cases Mean Value Median Value Median Value Economic Analysis for the Stage 2 DBPR July 2003 TTHM  IDSE Sensitivity Analysis 2 Lower ( 5th % tile) Upper ( 95th % tile) Lower ( 5th % tile) Upper ( 95th % tile) Lower ( 5th % tile) Upper ( 95th % tile) Lower ( 5th % tile) Upper ( 95th % tile) Lower ( 5th % tile) Upper ( 95th % tile) Lower ( 5th % tile) Upper ( 95th % tile)

2003  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $

2004  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $

2005  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $

2006 14.2 $ 12.4 $ 2.4 $ 32.3 $ 4.1 $ 3.8 $ 1.8 $ 7.5 $ 18.3 $ 16.1 $ 4.2 $ 39.8 $ 124.0 $ 108.0 $ 20.7 $ 281.8 $ 35.7 $ 32.8 $ 16.1 $ 65.2 $ 159.7 $ 140.8 $ 36.8 $ 347.0 $

2007 34.2 $ 29.8 $ 5.7 $ 77.8 $ 9.8 $ 9.0 $ 4.4 $ 18.0 $ 44.0 $ 38.8 $ 10.1 $ 95.7 $ 298.6 $ 260.1 $ 49.8 $ 678.8 $ 85.8 $ 78.9 $ 38.7 $ 156.8 $ 384.4 $ 339.0 $ 88.5 $ 835.6 $

2008 57.7 $ 50.2 $ 9.6 $ 131.0 $ 16.5 $ 15.2 $ 7.5 $ 30.2 $ 74.2 $ 65.4 $ 17.1 $ 161.3 $ 503.1 $ 438.2 $ 83.8 $ 1,143.7 $ 144.3 $ 132.8 $ 65.1 $ 263.7 $ 647.4 $ 571.0 $ 148.9 $ 1,407.4 $

2009 83.5 $ 72.7 $ 13.9 $ 189.9 $ 23.9 $ 22.0 $ 10.8 $ 43.7 $ 107.4 $ 94.8 $ 24.7 $ 233.6 $ 728.9 $ 634.9 $ 121.3 $ 1,657.1 $ 208.7 $ 192.2 $ 94.1 $ 381.4 $ 937.7 $ 827.0 $ 215.4 $ 2,038.5 $

2010 111.3 $ 97.0 $ 18.5 $ 253.1 $ 31.8 $ 29.3 $ 14.3 $ 58.2 $ 143.2 $ 126.3 $ 32.9 $ 311.2 $ 971.5 $ 846.1 $ 161.6 $ 2,208.8 $ 277.8 $ 255.9 $ 125.2 $ 507.6 $ 1,249.3 $ 1,102.0 $ 286.8 $ 2,716.3 $

2011 140.7 $ 122.6 $ 23.4 $ 320.0 $ 40.2 $ 37.0 $ 18.1 $ 73.5 $ 180.9 $ 159.6 $ 41.5 $ 393.5 $ 1,228.3 $ 1,069.8 $ 204.2 $ 2,792.8 $ 350.7 $ 323.0 $ 158.1 $ 641.7 $ 1,579.0 $ 1,392.8 $ 362.3 $ 3,434.5 $

2012 157.1 $ 136.8 $ 26.1 $ 357.2 $ 44.8 $ 41.3 $ 20.2 $ 82.0 $ 201.8 $ 178.0 $ 46.2 $ 439.2 $ 1,370.8 $ 1,193.8 $ 227.7 $ 3,117.0 $ 390.7 $ 360.0 $ 176.0 $ 715.7 $ 1,761.5 $ 1,553.8 $ 403.6 $ 3,832.6 $

2013 168.8 $ 147.0 $ 28.0 $ 383.8 $ 48.0 $ 44.3 $ 21.6 $ 87.9 $ 216.8 $ 191.3 $ 49.7 $ 471.8 $ 1,473.1 $ 1,282.9 $ 244.5 $ 3,349.9 $ 419.3 $ 386.4 $ 188.9 $ 767.5 $ 1,892.4 $ 1,669.3 $ 433.4 $ 4,117.4 $

2014 178.2 $ 155.2 $ 29.6 $ 405.3 $ 50.6 $ 46.7 $ 22.8 $ 92.7 $ 228.9 $ 201.9 $ 52.4 $ 498.1 $ 1,555.5 $ 1,354.6 $ 258.0 $ 3,537.5 $ 442.0 $ 407.5 $ 199.2 $ 809.3 $ 1,997.5 $ 1,762.1 $ 457.2 $ 4,346.8 $

2015 185.7 $ 161.7 $ 30.8 $ 422.3 $ 52.7 $ 48.6 $ 23.7 $ 96.5 $ 238.3 $ 210.3 $ 54.5 $ 518.8 $ 1,620.3 $ 1,411.1 $ 268.5 $ 3,685.4 $ 459.7 $ 423.9 $ 206.9 $ 842.0 $ 2,080.0 $ 1,835.0 $ 475.5 $ 4,527.4 $

2016 192.0 $ 167.2 $ 31.8 $ 436.7 $ 54.4 $ 50.1 $ 24.4 $ 99.6 $ 246.4 $ 217.3 $ 56.2 $ 536.3 $ 1,675.5 $ 1,459.1 $ 277.5 $ 3,811.0 $ 474.6 $ 437.7 $ 213.4 $ 869.1 $ 2,150.0 $ 1,896.7 $ 490.9 $ 4,680.2 $

2017 197.6 $ 172.0 $ 32.7 $ 449.4 $ 55.9 $ 51.5 $ 25.1 $ 102.4 $ 253.4 $ 223.6 $ 57.8 $ 551.8 $ 1,724.2 $ 1,501.5 $ 285.4 $ 3,922.3 $ 487.6 $ 449.7 $ 219.4 $ 893.3 $ 2,211.8 $ 1,951.2 $ 504.7 $ 4,815.5 $

2018 202.6 $ 176.5 $ 33.5 $ 461.0 $ 57.2 $ 52.8 $ 25.7 $ 104.9 $ 259.9 $ 229.2 $ 59.2 $ 565.9 $ 1,768.5 $ 1,540.1 $ 292.5 $ 4,023.4 $ 499.3 $ 460.6 $ 224.5 $ 915.2 $ 2,267.8 $ 2,000.7 $ 517.0 $ 4,938.6 $

2019 207.4 $ 180.6 $ 34.3 $ 471.8 $ 58.4 $ 53.9 $ 26.3 $ 107.2 $ 265.8 $ 234.5 $ 60.6 $ 578.9 $ 1,809.6 $ 1,575.8 $ 299.1 $ 4,117.2 $ 510.0 $ 470.4 $ 229.4 $ 935.2 $ 2,319.6 $ 2,046.3 $ 528.4 $ 5,052.3 $

2020 211.8 $ 184.4 $ 35.0 $ 481.9 $ 59.6 $ 54.9 $ 26.8 $ 109.4 $ 271.4 $ 239.4 $ 61.8 $ 591.3 $ 1,848.3 $ 1,609.5 $ 305.3 $ 4,205.5 $ 520.0 $ 479.4 $ 233.7 $ 954.7 $ 2,368.3 $ 2,088.9 $ 539.0 $ 5,160.2 $

2021 216.0 $ 188.1 $ 35.7 $ 491.5 $ 60.7 $ 55.9 $ 27.3 $ 111.4 $ 276.7 $ 244.0 $ 62.9 $ 602.9 $ 1,885.1 $ 1,641.5 $ 311.1 $ 4,289.5 $ 529.4 $ 487.9 $ 238.2 $ 972.1 $ 2,414.5 $ 2,129.4 $ 549.3 $ 5,261.6 $

2022 220.0 $ 191.6 $ 36.3 $ 500.7 $ 61.7 $ 56.9 $ 27.7 $ 113.4 $ 281.7 $ 248.5 $ 64.0 $ 614.1 $ 1,920.3 $ 1,672.1 $ 316.8 $ 4,370.1 $ 538.4 $ 496.2 $ 242.2 $ 989.3 $ 2,458.8 $ 2,168.3 $ 558.9 $ 5,359.4 $

2023 223.9 $ 195.0 $ 36.9 $ 509.7 $ 62.7 $ 57.8 $ 28.2 $ 115.2 $ 286.6 $ 252.8 $ 65.1 $ 624.9 $ 1,954.4 $ 1,701.8 $ 322.2 $ 4,448.1 $ 547.0 $ 504.2 $ 245.9 $ 1,005.7 $ 2,501.4 $ 2,206.0 $ 568.1 $ 5,453.7 $

2024 227.7 $ 198.3 $ 37.5 $ 518.4 $ 63.6 $ 58.7 $ 28.6 $ 117.0 $ 291.4 $ 257.0 $ 66.1 $ 635.3 $ 1,987.6 $ 1,730.6 $ 327.4 $ 4,523.8 $ 555.3 $ 512.0 $ 249.6 $ 1,020.8 $ 2,542.8 $ 2,242.6 $ 577.0 $ 5,544.6 $

2025 231.5 $ 201.5 $ 38.1 $ 526.8 $ 64.5 $ 59.5 $ 29.1 $ 118.6 $ 296.0 $ 261.0 $ 67.2 $ 645.5 $ 2,020.0 $ 1,758.7 $ 332.6 $ 4,597.8 $ 563.3 $ 519.3 $ 253.6 $ 1,035.3 $ 2,583.2 $ 2,278.0 $ 586.1 $ 5,633.1 $

2026 235.1 $ 204.7 $ 38.7 $ 535.2 $ 65.4 $ 60.4 $ 29.5 $ 120.3 $ 300.5 $ 265.0 $ 68.1 $ 655.4 $ 2,051.7 $ 1,786.3 $ 337.6 $ 4,670.4 $ 571.1 $ 526.8 $ 257.1 $ 1,049.8 $ 2,622.8 $ 2,313.1 $ 594.7 $ 5,720.3 $

2027 238.7 $ 207.8 $ 39.2 $ 543.3 $ 66.3 $ 61.2 $ 29.8 $ 121.9 $ 305.0 $ 269.0 $ 69.1 $ 665.3 $ 2,083.0 $ 1,813.5 $ 342.5 $ 4,741.9 $ 578.7 $ 534.1 $ 260.3 $ 1,064.2 $ 2,661.6 $ 2,347.6 $ 602.8 $ 5,806.1 $

Total 3,735.7 $ 3,253.0 $ 617.6 $ 8,499.1 $ 1,052.9 $ 970.7 $ 473.9 $ 1,931.4 $ 4,788.6 $ 4,223.7 $ 1,091.5 $ 10,430.4 $ 32,602.3 $ 28,390.0 $ 5,390.0 $ 74,173.7 $ 9,189.2 $ 8,471.6 $ 4,135.6 $ 16,855.5 $ 41,791.5 $ 36,861.6 $ 9,525.5 $ 91,029.2 $

Notes: All values in millions of year 2000 dollars.

Detail may not add exactly to totals due to independent rounding.

Source: Derived from Exhibits F. 17a and F. 17b. Exhibit F. 17c Projections of Yearly Benefits, WTP for Bronchitis as Basis for Non Fatal Cases Mean Value Median Value 90 Percent Confidence Bound Mean Value Median Value 90 Percent Confidence Bound Median Value 90 Percent Confidence Bound Mean Value Median Value Mean Value Median Value 90 Percent Confidence Bound 90 Percent Confidence Bound Non Fatal Cases Total 2% Estimate of PAR 17% Estimate of PAR ( All Water Systems)

Total Fatal Cases Fatal Cases Year Mean Value Median Value 90 Percent Confidence Bound Non Fatal Cases Mean Value Economic Analysis for the Stage 2 DBPR July 2003 TTHM  IDSE Sensitivity Analysis 2 Lower ( 5th % tile) Upper ( 95th % tile) Lower ( 5th % tile) Upper ( 95th % tile) Lower ( 5th % tile) Upper ( 95th % tile) Lower ( 5th % tile) Upper ( 95th % tile) Lower ( 5th % tile) Upper ( 95th % tile) Lower ( 5th % tile) Upper ( 95th % tile)

2003  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $

2004  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $

2005  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $

2006 13.0 $ 11.3 $ 2.2 $ 29.5 $ 3.7 $ 3.4 $ 1.7 $ 6.8 $ 16.7 $ 14.8 $ 3.9 $ 36.4 $ 113.5 $ 98.8 $ 18.9 $ 257.9 $ 32.6 $ 30.0 $ 14.8 $ 59.7 $ 146.1 $ 128.9 $ 33.7 $ 317.6 $

2007 30.4 $ 26.5 $ 5.1 $ 69.1 $ 8.7 $ 8.0 $ 3.9 $ 16.0 $ 39.1 $ 34.5 $ 9.0 $ 85.1 $ 265.3 $ 231.1 $ 44.2 $ 603.1 $ 76.2 $ 70.1 $ 34.4 $ 139.3 $ 341.5 $ 301.2 $ 78.6 $ 742.4 $

2008 49.7 $ 43.3 $ 8.3 $ 113.0 $ 14.3 $ 13.1 $ 6.4 $ 26.1 $ 64.0 $ 56.4 $ 14.7 $ 139.1 $ 434.0 $ 378.0 $ 72.3 $ 986.5 $ 124.5 $ 114.5 $ 56.2 $ 227.5 $ 558.5 $ 492.5 $ 128.5 $ 1,214.0 $

2009 69.9 $ 60.9 $ 11.6 $ 159.0 $ 20.0 $ 18.4 $ 9.0 $ 36.6 $ 90.0 $ 79.4 $ 20.7 $ 195.6 $ 610.5 $ 531.7 $ 101.6 $ 1,387.8 $ 174.8 $ 160.9 $ 78.8 $ 319.4 $ 785.3 $ 692.6 $ 180.4 $ 1,707.2 $

2010 90.5 $ 78.8 $ 15.1 $ 205.8 $ 25.9 $ 23.8 $ 11.7 $ 47.3 $ 116.4 $ 102.7 $ 26.7 $ 253.1 $ 789.9 $ 688.0 $ 131.4 $ 1,795.9 $ 225.9 $ 208.0 $ 101.8 $ 412.7 $ 1,015.8 $ 896.0 $ 233.2 $ 2,208.6 $

2011 111.1 $ 96.8 $ 18.5 $ 252.6 $ 31.7 $ 29.2 $ 14.3 $ 58.0 $ 142.8 $ 126.0 $ 32.8 $ 310.7 $ 969.6 $ 844.5 $ 161.2 $ 2,204.7 $ 276.8 $ 255.0 $ 124.8 $ 506.6 $ 1,246.5 $ 1,099.5 $ 286.0 $ 2,711.3 $

2012 120.4 $ 104.8 $ 20.0 $ 273.7 $ 34.3 $ 31.6 $ 15.5 $ 62.8 $ 154.7 $ 136.5 $ 35.4 $ 336.6 $ 1,050.6 $ 915.0 $ 174.5 $ 2,388.9 $ 299.5 $ 275.9 $ 134.9 $ 548.5 $ 1,350.1 $ 1,190.9 $ 309.4 $ 2,937.4 $

2013 125.6 $ 109.4 $ 20.8 $ 285.6 $ 35.7 $ 32.9 $ 16.1 $ 65.4 $ 161.3 $ 142.3 $ 37.0 $ 351.1 $ 1,096.1 $ 954.6 $ 181.9 $ 2,492.7 $ 312.0 $ 287.5 $ 140.6 $ 571.1 $ 1,408.1 $ 1,242.1 $ 322.5 $ 3,063.8 $

2014 128.8 $ 112.1 $ 21.4 $ 292.8 $ 36.6 $ 33.7 $ 16.5 $ 67.0 $ 165.3 $ 145.9 $ 37.8 $ 359.8 $ 1,123.7 $ 978.6 $ 186.4 $ 2,555.6 $ 319.3 $ 294.4 $ 143.9 $ 584.6 $ 1,443.0 $ 1,273.0 $ 330.3 $ 3,140.2 $

2015 130.2 $ 113.4 $ 21.6 $ 296.2 $ 36.9 $ 34.1 $ 16.6 $ 67.7 $ 167.2 $ 147.5 $ 38.2 $ 363.8 $ 1,136.5 $ 989.7 $ 188.4 $ 2,584.8 $ 322.4 $ 297.3 $ 145.1 $ 590.6 $ 1,458.9 $ 1,287.0 $ 333.5 $ 3,175.4 $

2016 130.7 $ 113.8 $ 21.7 $ 297.4 $ 37.0 $ 34.1 $ 16.6 $ 67.8 $ 167.8 $ 148.0 $ 38.3 $ 365.2 $ 1,140.9 $ 993.6 $ 189.0 $ 2,595.1 $ 323.2 $ 298.0 $ 145.3 $ 591.8 $ 1,464.1 $ 1,291.6 $ 334.2 $ 3,187.0 $

2017 130.6 $ 113.7 $ 21.6 $ 297.1 $ 36.9 $ 34.1 $ 16.6 $ 67.7 $ 167.6 $ 147.8 $ 38.2 $ 364.8 $ 1,139.9 $ 992.7 $ 188.7 $ 2,593.1 $ 322.4 $ 297.3 $ 145.0 $ 590.6 $ 1,462.3 $ 1,290.0 $ 333.7 $ 3,183.6 $

2018 130.1 $ 113.3 $ 21.5 $ 295.9 $ 36.7 $ 33.9 $ 16.5 $ 67.3 $ 166.8 $ 147.1 $ 38.0 $ 363.2 $ 1,135.1 $ 988.5 $ 187.7 $ 2,582.5 $ 320.5 $ 295.6 $ 144.1 $ 587.4 $ 1,455.6 $ 1,284.2 $ 331.9 $ 3,169.9 $

2019 129.2 $ 112.5 $ 21.4 $ 294.0 $ 36.4 $ 33.6 $ 16.4 $ 66.8 $ 165.6 $ 146.1 $ 37.7 $ 360.8 $ 1,127.7 $ 982.0 $ 186.4 $ 2,565.7 $ 317.8 $ 293.1 $ 142.9 $ 582.8 $ 1,445.5 $ 1,275.2 $ 329.3 $ 3,148.4 $

2020 128.1 $ 111.6 $ 21.2 $ 291.5 $ 36.1 $ 33.2 $ 16.2 $ 66.2 $ 164.2 $ 144.8 $ 37.4 $ 357.7 $ 1,118.2 $ 973.8 $ 184.7 $ 2,544.4 $ 314.6 $ 290.1 $ 141.4 $ 577.6 $ 1,432.9 $ 1,263.8 $ 326.1 $ 3,122.0 $

2021 126.9 $ 110.5 $ 20.9 $ 288.7 $ 35.6 $ 32.8 $ 16.0 $ 65.4 $ 162.5 $ 143.3 $ 37.0 $ 354.1 $ 1,107.3 $ 964.2 $ 182.8 $ 2,519.6 $ 311.0 $ 286.6 $ 139.9 $ 571.0 $ 1,418.3 $ 1,250.8 $ 322.7 $ 3,090.7 $

2022 125.5 $ 109.3 $ 20.7 $ 285.6 $ 35.2 $ 32.4 $ 15.8 $ 64.6 $ 160.7 $ 141.7 $ 36.5 $ 350.2 $ 1,095.1 $ 953.6 $ 180.6 $ 2,492.2 $ 307.0 $ 283.0 $ 138.1 $ 564.2 $ 1,402.2 $ 1,236.6 $ 318.8 $ 3,056.4 $

2023 124.0 $ 108.0 $ 20.4 $ 282.2 $ 34.7 $ 32.0 $ 15.6 $ 63.8 $ 158.7 $ 140.0 $ 36.0 $ 346.0 $ 1,082.1 $ 942.2 $ 178.4 $ 2,462.8 $ 302.9 $ 279.2 $ 136.2 $ 556.8 $ 1,385.0 $ 1,221.4 $ 314.6 $ 3,019.6 $

2024 122.4 $ 106.6 $ 20.2 $ 278.6 $ 34.2 $ 31.5 $ 15.4 $ 62.9 $ 156.6 $ 138.1 $ 35.5 $ 341.5 $ 1,068.4 $ 930.3 $ 176.0 $ 2,431.8 $ 298.5 $ 275.2 $ 134.2 $ 548.7 $ 1,366.9 $ 1,205.5 $ 310.2 $ 2,980.5 $

2025 120.8 $ 105.2 $ 19.9 $ 275.0 $ 33.7 $ 31.1 $ 15.2 $ 61.9 $ 154.5 $ 136.2 $ 35.0 $ 336.9 $ 1,054.2 $ 917.9 $ 173.6 $ 2,399.6 $ 294.0 $ 271.0 $ 132.3 $ 540.3 $ 1,348.2 $ 1,188.9 $ 305.9 $ 2,939.9 $

2026 119.1 $ 103.7 $ 19.6 $ 271.2 $ 33.2 $ 30.6 $ 14.9 $ 61.0 $ 152.3 $ 134.3 $ 34.5 $ 332.1 $ 1,039.6 $ 905.1 $ 171.0 $ 2,366.5 $ 289.4 $ 266.9 $ 130.3 $ 531.9 $ 1,328.9 $ 1,172.0 $ 301.3 $ 2,898.4 $

2027 117.4 $ 102.2 $ 19.3 $ 267.3 $ 32.6 $ 30.1 $ 14.7 $ 60.0 $ 150.0 $ 132.3 $ 34.0 $ 327.3 $ 1,024.7 $ 892.1 $ 168.5 $ 2,332.7 $ 284.7 $ 262.8 $ 128.1 $ 523.5 $ 1,309.3 $ 1,154.9 $ 296.6 $ 2,856.2 $

Total 2,374.5 $ 2,067.8 $ 392.8 $ 5,401.9 $ 670.3 $ 617.9 $ 301.7 $ 1,229.1 $ 3,044.8 $ 2,685.7 $ 694.5 $ 6,631.0 $ 20,723.1 $ 18,045.9 $ 3,428.1 $ 47,143.7 $ 5,849.8 $ 5,392.5 $ 2,633.0 $ 10,726.7 $ 26,572.8 $ 23,438.4 $ 6,061.1 $ 57,870.4 $

Ann. 136.4 $ 118.7 $ 22.6 $ 310.2 $ 38.5 $ 35.5 $ 17.3 $ 70.6 $ 174.9 $ 154.2 $ 39.9 $ 380.8 $ 1,190.1 $ 1,036.3 $ 196.9 $ 2,707.4 $ 335.9 $ 309.7 $ 151.2 $ 616.0 $ 1,526.0 $ 1,346.0 $ 348.1 $ 3,323.4 $

Notes:

Source: Derived from Exhibit F. 17c. Non Fatal Cases Mean Value Median Value Median Value 2% Estimate of PAR Exhibit F. 17d Present Value of Benefits Yearly Projections, WTP for Bronchitis as Basis for Non Fatal Cases, at 3% Discount Rate ( All Water Systems)

Total Year 17% Estimate of PAR 90 Percent Confidence Bound Mean Value 90 Percent Confidence Bound 90 Percent Confidence Bound Detail may not add exactly to totals due to independent rounding. Mean Value Median Value 90 Percent Confidence Bound Mean Value Median Value Mean Value Median Value 90 Percent Confidence Bound Ann. = value of total annualized at discount rate. Fatal Cases Fatal Cases Non Fatal Cases Total Mean Value Median Value 90 Percent Confidence Bound Present values in millions of 2000 dollars. Estimates are discounted to 2003.

Economic Analysis for the Stage 2 DBPR July 2003 TTHM  IDSE Sensitivity Analysis 2 Lower ( 5th % tile) Upper ( 95th % tile) Lower ( 5th % tile) Upper ( 95th % tile) Lower ( 5th % tile) Upper ( 95th % tile) Lower ( 5th % tile) Upper ( 95th % tile) Lower ( 5th % tile) Upper ( 95th % tile) Lower ( 5th % tile) Upper ( 95th % tile)

2003  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $

2004  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $

2005  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $

2006 11.6 $ 10.1 $ 1.9 $ 26.4 $ 3.3 $ 3.1 $ 1.5 $ 6.1 $ 14.9 $ 13.2 $ 3.4 $ 32.5 $ 101.2 $ 88.2 $ 16.9 $ 230.0 $ 29.1 $ 26.8 $ 13.2 $ 53.2 $ 130.3 $ 114.9 $ 30.1 $ 283.3 $

2007 26.1 $ 22.7 $ 4.4 $ 59.3 $ 7.5 $ 6.9 $ 3.4 $ 13.7 $ 33.6 $ 29.6 $ 7.7 $ 73.0 $ 227.8 $ 198.4 $ 38.0 $ 517.8 $ 65.4 $ 60.2 $ 29.5 $ 119.6 $ 293.3 $ 258.6 $ 67.5 $ 637.5 $

2008 41.1 $ 35.8 $ 6.8 $ 93.4 $ 11.8 $ 10.8 $ 5.3 $ 21.5 $ 52.9 $ 46.6 $ 12.2 $ 115.0 $ 358.7 $ 312.4 $ 59.8 $ 815.4 $ 102.9 $ 94.7 $ 46.4 $ 188.0 $ 461.6 $ 407.1 $ 106.2 $ 1,003.4 $

2009 55.7 $ 48.5 $ 9.3 $ 126.5 $ 15.9 $ 14.7 $ 7.2 $ 29.1 $ 71.6 $ 63.1 $ 16.4 $ 155.6 $ 485.7 $ 423.0 $ 80.9 $ 1,104.2 $ 139.1 $ 128.0 $ 62.7 $ 254.1 $ 624.8 $ 551.1 $ 143.6 $ 1,358.3 $

2010 69.3 $ 60.4 $ 11.5 $ 157.6 $ 19.8 $ 18.3 $ 8.9 $ 36.2 $ 89.1 $ 78.6 $ 20.5 $ 193.8 $ 605.0 $ 526.9 $ 100.6 $ 1,375.5 $ 173.0 $ 159.3 $ 78.0 $ 316.1 $ 778.0 $ 686.3 $ 178.6 $ 1,691.6 $

2011 81.9 $ 71.3 $ 13.6 $ 186.2 $ 23.4 $ 21.5 $ 10.5 $ 42.8 $ 105.3 $ 92.9 $ 24.2 $ 229.0 $ 714.9 $ 622.6 $ 118.8 $ 1,625.4 $ 204.1 $ 188.0 $ 92.0 $ 373.5 $ 919.0 $ 810.6 $ 210.8 $ 1,998.9 $

2012 85.4 $ 74.4 $ 14.2 $ 194.3 $ 24.4 $ 22.4 $ 11.0 $ 44.6 $ 109.8 $ 96.8 $ 25.2 $ 238.9 $ 745.6 $ 649.4 $ 123.8 $ 1,695.4 $ 212.5 $ 195.8 $ 95.7 $ 389.3 $ 958.1 $ 845.2 $ 219.6 $ 2,084.7 $

2013 85.8 $ 74.7 $ 14.2 $ 195.1 $ 24.4 $ 22.5 $ 11.0 $ 44.7 $ 110.2 $ 97.2 $ 25.2 $ 239.8 $ 748.8 $ 652.2 $ 124.3 $ 1,702.9 $ 213.1 $ 196.4 $ 96.0 $ 390.2 $ 962.0 $ 848.6 $ 220.3 $ 2,093.1 $

2014 84.7 $ 73.7 $ 14.0 $ 192.6 $ 24.1 $ 22.2 $ 10.8 $ 44.1 $ 108.7 $ 95.9 $ 24.9 $ 236.6 $ 739.0 $ 643.6 $ 122.6 $ 1,680.6 $ 210.0 $ 193.6 $ 94.6 $ 384.5 $ 949.0 $ 837.2 $ 217.2 $ 2,065.1 $

2015 82.4 $ 71.8 $ 13.7 $ 187.5 $ 23.4 $ 21.6 $ 10.5 $ 42.8 $ 105.8 $ 93.4 $ 24.2 $ 230.3 $ 719.4 $ 626.5 $ 119.2 $ 1,636.3 $ 204.1 $ 188.2 $ 91.9 $ 373.9 $ 923.6 $ 814.7 $ 211.1 $ 2,010.2 $

2016 79.7 $ 69.4 $ 13.2 $ 181.2 $ 22.6 $ 20.8 $ 10.1 $ 41.3 $ 102.2 $ 90.2 $ 23.3 $ 222.5 $ 695.3 $ 605.5 $ 115.1 $ 1,581.4 $ 196.9 $ 181.6 $ 88.5 $ 360.7 $ 892.2 $ 787.1 $ 203.7 $ 1,942.1 $

2017 76.6 $ 66.7 $ 12.7 $ 174.3 $ 21.7 $ 20.0 $ 9.7 $ 39.7 $ 98.3 $ 86.7 $ 22.4 $ 214.0 $ 668.7 $ 582.3 $ 110.7 $ 1,521.1 $ 189.1 $ 174.4 $ 85.1 $ 346.4 $ 857.8 $ 756.7 $ 195.7 $ 1,867.5 $

2018 73.4 $ 64.0 $ 12.1 $ 167.1 $ 20.7 $ 19.1 $ 9.3 $ 38.0 $ 94.2 $ 83.1 $ 21.5 $ 205.1 $ 641.0 $ 558.2 $ 106.0 $ 1,458.3 $ 181.0 $ 166.9 $ 81.4 $ 331.7 $ 822.0 $ 725.1 $ 187.4 $ 1,790.0 $

2019 70.2 $ 61.2 $ 11.6 $ 159.8 $ 19.8 $ 18.3 $ 8.9 $ 36.3 $ 90.0 $ 79.4 $ 20.5 $ 196.1 $ 613.0 $ 533.8 $ 101.3 $ 1,394.6 $ 172.8 $ 159.3 $ 77.7 $ 316.8 $ 785.7 $ 693.1 $ 179.0 $ 1,711.4 $

2020 67.0 $ 58.4 $ 11.1 $ 152.6 $ 18.9 $ 17.4 $ 8.5 $ 34.6 $ 85.9 $ 75.8 $ 19.6 $ 187.2 $ 585.1 $ 509.5 $ 96.6 $ 1,331.3 $ 164.6 $ 151.8 $ 74.0 $ 302.2 $ 749.7 $ 661.3 $ 170.6 $ 1,633.6 $

2021 63.9 $ 55.6 $ 10.5 $ 145.4 $ 17.9 $ 16.5 $ 8.1 $ 33.0 $ 81.9 $ 72.2 $ 18.6 $ 178.4 $ 557.7 $ 485.7 $ 92.1 $ 1,269.1 $ 156.6 $ 144.4 $ 70.5 $ 287.6 $ 714.4 $ 630.0 $ 162.5 $ 1,556.7 $

2022 60.8 $ 53.0 $ 10.0 $ 138.5 $ 17.1 $ 15.7 $ 7.7 $ 31.3 $ 77.9 $ 68.7 $ 17.7 $ 169.8 $ 531.0 $ 462.4 $ 87.6 $ 1,208.4 $ 148.9 $ 137.2 $ 67.0 $ 273.5 $ 679.9 $ 599.6 $ 154.6 $ 1,481.9 $

2023 57.9 $ 50.4 $ 9.5 $ 131.7 $ 16.2 $ 14.9 $ 7.3 $ 29.8 $ 74.1 $ 65.3 $ 16.8 $ 161.5 $ 505.1 $ 439.8 $ 83.3 $ 1,149.5 $ 141.4 $ 130.3 $ 63.6 $ 259.9 $ 646.4 $ 570.1 $ 146.8 $ 1,409.3 $

2024 55.0 $ 47.9 $ 9.1 $ 125.2 $ 15.4 $ 14.2 $ 6.9 $ 28.2 $ 70.4 $ 62.1 $ 16.0 $ 153.4 $ 480.0 $ 418.0 $ 79.1 $ 1,092.6 $ 134.1 $ 123.7 $ 60.3 $ 246.5 $ 614.1 $ 541.6 $ 139.4 $ 1,339.1 $

2025 52.2 $ 45.5 $ 8.6 $ 118.9 $ 14.6 $ 13.4 $ 6.6 $ 26.8 $ 66.8 $ 58.9 $ 15.2 $ 145.7 $ 455.9 $ 397.0 $ 75.1 $ 1,037.8 $ 127.1 $ 117.2 $ 57.2 $ 233.7 $ 583.1 $ 514.2 $ 132.3 $ 1,271.5 $

2026 49.6 $ 43.2 $ 8.2 $ 112.9 $ 13.8 $ 12.7 $ 6.2 $ 25.4 $ 63.4 $ 55.9 $ 14.4 $ 138.3 $ 432.8 $ 376.8 $ 71.2 $ 985.2 $ 120.5 $ 111.1 $ 54.2 $ 221.5 $ 553.3 $ 487.9 $ 125.4 $ 1,206.7 $

2027 47.1 $ 41.0 $ 7.7 $ 107.1 $ 13.1 $ 12.1 $ 5.9 $ 24.0 $ 60.1 $ 53.0 $ 13.6 $ 131.2 $ 410.6 $ 357.5 $ 67.5 $ 934.9 $ 114.1 $ 105.3 $ 51.3 $ 209.8 $ 524.7 $ 462.8 $ 118.8 $ 1,144.7 $

Total 1,377.6 $ 1,199.6 $ 228.1 $ 3,133.6 $ 389.6 $ 359.1 $ 175.4 $ 714.2 $ 1,767.2 $ 1,558.8 $ 403.5 $ 3,847.8 $ 12,022.5 $ 10,469.6 $ 1,990.4 $ 27,347.9 $ 3,400.4 $ 3,134.3 $ 1,530.8 $ 6,232.7 $ 15,422.9 $ 13,603.8 $ 3,521.2 $ 33,580.6 $

Ann. 118.2 $ 102.9 $ 19.6 $ 268.9 $ 33.4 $ 30.8 $ 15.1 $ 61.3 $ 151.6 $ 133.8 $ 34.6 $ 330.2 $ 1,031.7 $ 898.4 $ 170.8 $ 2,346.7 $ 291.8 $ 269.0 $ 131.4 $ 534.8 $ 1,323.4 $ 1,167.4 $ 302.2 $ 2,881.6 $

Notes:

Source: Derived from Exhibit F. 17c. Ann. = value of total annualized at discount rate. 90 Percent Confidence Bound Mean Value Median Value Detail may not add exactly to totals due to independent rounding. Mean Value Median Value 90 Percent Confidence Bound Mean Value Median Value 90 Percent Confidence Bound Median Value Median Value 90 Percent Confidence Bound Exhibit F. 17e Present Value of Benefits Yearly Projections, WTP for Bronchitis as Basis for Non Fatal Cases, at 7% Discount Rate Present values in millions of 2000 dollars. Estimates are discounted to 2003. Mean Value Non Fatal Cases Total 2% Estimate of PAR 17% Estimate of PAR 90 Percent Confidence Bound Mean Value ( All Water Systems)

Total Fatal Cases Fatal Cases Year Mean Value Median Value 90 Percent Confidence Bound Non Fatal Cases Economic Analysis for the Stage 2 DBPR July 2003 TTHM  IDSE Sensitivity Analysis 2 Year < 100 101 500 501 1K 1,001 3,3K 3,301 10K 10,001 50K 50,001 100K 100,001 1M > 1M Total < 100 101 500 501 1K 1,001 3,3K 3,301 10K 10,001 50K 50,001 100K 100,001 1M > 1M Total 2003  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $

2004  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $

2005  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $

2006 0.0 $ 0.0 $ 0.0 $ 0.2 $ 0.5 $ 2.6 $ 1.7 $ 6.4 $ 5.4 $ 16.7 $ 0.0 $ 0.3 $ 0.4 $ 1.7 $ 4.0 $ 23.0 $ 14.5 $ 55.6 $ 46.7 $ 146.1 $

2007 0.0 $ 0.1 $ 0.1 $ 0.4 $ 1.1 $ 6.2 $ 3.9 $ 14.9 $ 12.5 $ 39.1 $ 0.1 $ 0.6 $ 0.8 $ 3.9 $ 9.2 $ 53.7 $ 34.0 $ 130.0 $ 109.2 $ 341.5 $

2008 0.0 $ 0.1 $ 0.2 $ 0.7 $ 1.7 $ 10.1 $ 6.4 $ 24.4 $ 20.5 $ 64.0 $ 0.2 $ 1.0 $ 1.4 $ 6.3 $ 15.1 $ 87.8 $ 55.5 $ 212.6 $ 178.5 $ 558.5 $

2009 0.0 $ 0.2 $ 0.2 $ 1.0 $ 2.4 $ 14.1 $ 8.9 $ 34.3 $ 28.8 $ 90.0 $ 0.2 $ 1.4 $ 1.9 $ 8.9 $ 21.3 $ 123.5 $ 78.1 $ 298.9 $ 251.0 $ 785.3 $

2010 0.0 $ 0.2 $ 0.3 $ 1.3 $ 3.2 $ 18.3 $ 11.6 $ 44.3 $ 37.2 $ 116.4 $ 0.3 $ 1.9 $ 2.5 $ 11.5 $ 27.5 $ 159.7 $ 101.0 $ 386.7 $ 324.7 $ 1,015.8 $

2011 0.0 $ 0.3 $ 0.4 $ 1.6 $ 3.9 $ 22.5 $ 14.2 $ 54.4 $ 45.7 $ 142.8 $ 0.3 $ 2.3 $ 3.1 $ 14.1 $ 33.7 $ 196.0 $ 124.0 $ 474.5 $ 398.4 $ 1,246.5 $

2012 0.0 $ 0.3 $ 0.4 $ 1.9 $ 4.6 $ 24.2 $ 15.3 $ 58.6 $ 49.2 $ 154.7 $ 0.4 $ 2.7 $ 3.6 $ 16.7 $ 39.9 $ 211.4 $ 133.7 $ 511.8 $ 429.8 $ 1,350.1 $

2013 0.1 $ 0.4 $ 0.5 $ 2.2 $ 5.3 $ 25.1 $ 15.9 $ 60.9 $ 51.1 $ 161.3 $ 0.5 $ 3.1 $ 4.2 $ 19.2 $ 46.0 $ 219.4 $ 138.8 $ 531.1 $ 445.9 $ 1,408.1 $

2014 0.1 $ 0.4 $ 0.5 $ 2.5 $ 6.0 $ 25.6 $ 16.2 $ 62.0 $ 52.1 $ 165.3 $ 0.5 $ 3.5 $ 4.7 $ 21.7 $ 52.0 $ 223.6 $ 141.4 $ 541.2 $ 454.4 $ 1,443.0 $

2015 0.1 $ 0.4 $ 0.6 $ 2.6 $ 6.2 $ 25.8 $ 16.3 $ 62.6 $ 52.5 $ 167.2 $ 0.5 $ 3.7 $ 4.9 $ 22.7 $ 54.4 $ 225.5 $ 142.6 $ 546.0 $ 458.4 $ 1,458.9 $

2016 0.1 $ 0.4 $ 0.6 $ 2.7 $ 6.4 $ 25.9 $ 16.4 $ 62.7 $ 52.7 $ 167.8 $ 0.6 $ 3.8 $ 5.0 $ 23.2 $ 55.6 $ 226.1 $ 143.0 $ 547.3 $ 459.5 $ 1,464.1 $

2017 0.1 $ 0.4 $ 0.6 $ 2.7 $ 6.4 $ 25.9 $ 16.4 $ 62.6 $ 52.5 $ 167.6 $ 0.6 $ 3.8 $ 5.1 $ 23.5 $ 56.2 $ 225.6 $ 142.7 $ 546.2 $ 458.6 $ 1,462.3 $

2018 0.1 $ 0.4 $ 0.6 $ 2.7 $ 6.5 $ 25.7 $ 16.3 $ 62.3 $ 52.3 $ 166.8 $ 0.6 $ 3.8 $ 5.1 $ 23.5 $ 56.3 $ 224.5 $ 142.0 $ 543.5 $ 456.3 $ 1,455.6 $

2019 0.1 $ 0.4 $ 0.6 $ 2.7 $ 6.4 $ 25.5 $ 16.2 $ 61.8 $ 51.9 $ 165.6 $ 0.6 $ 3.8 $ 5.1 $ 23.5 $ 56.2 $ 222.9 $ 141.0 $ 539.5 $ 453.0 $ 1,445.5 $

2020 0.1 $ 0.4 $ 0.6 $ 2.7 $ 6.4 $ 25.3 $ 16.0 $ 61.3 $ 51.4 $ 164.2 $ 0.6 $ 3.8 $ 5.1 $ 23.4 $ 55.9 $ 220.8 $ 139.7 $ 534.7 $ 448.9 $ 1,432.9 $

2021 0.1 $ 0.4 $ 0.6 $ 2.7 $ 6.4 $ 25.0 $ 15.8 $ 60.6 $ 50.9 $ 162.5 $ 0.6 $ 3.8 $ 5.0 $ 23.2 $ 55.5 $ 218.6 $ 138.2 $ 529.1 $ 444.3 $ 1,418.3 $

2022 0.1 $ 0.4 $ 0.6 $ 2.6 $ 6.3 $ 24.8 $ 15.7 $ 59.9 $ 50.3 $ 160.7 $ 0.6 $ 3.7 $ 5.0 $ 23.0 $ 55.0 $ 216.1 $ 136.7 $ 523.0 $ 439.2 $ 1,402.2 $

2023 0.1 $ 0.4 $ 0.6 $ 2.6 $ 6.2 $ 24.4 $ 15.5 $ 59.2 $ 49.7 $ 158.7 $ 0.5 $ 3.7 $ 4.9 $ 22.7 $ 54.4 $ 213.4 $ 135.0 $ 516.6 $ 433.7 $ 1,385.0 $

2024 0.1 $ 0.4 $ 0.6 $ 2.6 $ 6.2 $ 24.1 $ 15.3 $ 58.4 $ 49.0 $ 156.6 $ 0.5 $ 3.7 $ 4.9 $ 22.5 $ 53.8 $ 210.6 $ 133.2 $ 509.8 $ 428.0 $ 1,366.9 $

2025 0.1 $ 0.4 $ 0.6 $ 2.5 $ 6.1 $ 23.8 $ 15.1 $ 57.6 $ 48.4 $ 154.5 $ 0.5 $ 3.6 $ 4.8 $ 22.2 $ 53.1 $ 207.7 $ 131.4 $ 502.7 $ 422.1 $ 1,348.2 $

2026 0.1 $ 0.4 $ 0.5 $ 2.5 $ 6.0 $ 23.5 $ 14.8 $ 56.8 $ 47.7 $ 152.3 $ 0.5 $ 3.6 $ 4.7 $ 21.9 $ 52.4 $ 204.7 $ 129.5 $ 495.5 $ 416.1 $ 1,328.9 $

2027 0.1 $ 0.4 $ 0.5 $ 2.5 $ 5.9 $ 23.1 $ 14.6 $ 55.9 $ 47.0 $ 150.0 $ 0.5 $ 3.5 $ 4.7 $ 21.6 $ 51.7 $ 201.7 $ 127.6 $ 488.2 $ 409.9 $ 1,309.3 $

Total 1.1 $ 7.5 $ 10.0 $ 45.9 $ 109.9 $ 471.6 $ 298.3 $ 1,141.8 $ 958.7 $ 3,044.8 $ 9.6 $ 65.3 $ 86.9 $ 400.6 $ 959.5 $ 4,116.0 $ 2,603.5 $ 9,964.6 $ 8,366.9 $ 26,572.8 $

Ann. 0.1 $ 0.4 $ 0.6 $ 2.6 $ 6.3 $ 27.1 $ 17.1 $ 65.6 $ 55.1 $ 174.9 $ 0.6 $ 3.7 $ 5.0 $ 23.0 $ 55.1 $ 236.4 $ 149.5 $ 572.2 $ 480.5 $ 1,526.0 $

Notes:

Source: Derived from Exhibits F. 17a and F. 17b. Exhibit F. 17f Mean Present Value of Benefits Yearly Projections, WTP for Bronchitis as Basis for Non Fatal Cases, at 3% Discount Rate, by System Size ( All Systems)

17% Estimate of PAR Present values in millions of 2000 dollars. Estimates are discounted to 2003.

Detail may not add exactly to totals due to independent rounding. 2% Estimate of PAR Ann. = value of total annualized at discount rate.

Economic Analysis for the Stage 2 DBPR July 2003 TTHM  IDSE Sensitivity Analysis 2 Year < 100 101 500 501 1K 1,001 3,3K 3,301 10K 10,001 50K 50,001 100K 100,001 1M > 1M Total < 100 101 500 501 1K 1,001 3,3K 3,301 10K 10,001 50K 50,001 100K 100,001 1M > 1M Total 2003  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $

2004  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $

2005  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $  $

2006 0.0 $ 0.0 $ 0.0 $ 0.2 $ 0.4 $ 2.3 $ 1.5 $ 5.7 $ 4.8 $ 14.9 $ 0.0 $ 0.2 $ 0.3 $ 1.5 $ 3.5 $ 20.5 $ 13.0 $ 49.6 $ 41.7 $ 130.3 $

2007 0.0 $ 0.1 $ 0.1 $ 0.4 $ 0.9 $ 5.3 $ 3.3 $ 12.8 $ 10.7 $ 33.6 $ 0.1 $ 0.5 $ 0.7 $ 3.3 $ 7.9 $ 46.1 $ 29.2 $ 111.6 $ 93.7 $ 293.3 $

2008 0.0 $ 0.1 $ 0.1 $ 0.6 $ 1.4 $ 8.3 $ 5.3 $ 20.1 $ 16.9 $ 52.9 $ 0.1 $ 0.8 $ 1.1 $ 5.2 $ 12.5 $ 72.6 $ 45.9 $ 175.7 $ 147.6 $ 461.6 $

2009 0.0 $ 0.1 $ 0.2 $ 0.8 $ 1.9 $ 11.3 $ 7.1 $ 27.3 $ 22.9 $ 71.6 $ 0.2 $ 1.2 $ 1.5 $ 7.1 $ 16.9 $ 98.3 $ 62.1 $ 237.9 $ 199.7 $ 624.8 $

2010 0.0 $ 0.2 $ 0.2 $ 1.0 $ 2.4 $ 14.0 $ 8.9 $ 33.9 $ 28.5 $ 89.1 $ 0.2 $ 1.4 $ 1.9 $ 8.8 $ 21.1 $ 122.3 $ 77.4 $ 296.2 $ 248.7 $ 778.0 $

2011 0.0 $ 0.2 $ 0.3 $ 1.2 $ 2.9 $ 16.6 $ 10.5 $ 40.1 $ 33.7 $ 105.3 $ 0.2 $ 1.7 $ 2.3 $ 10.4 $ 24.9 $ 144.5 $ 91.4 $ 349.9 $ 293.8 $ 919.0 $

2012 0.0 $ 0.2 $ 0.3 $ 1.4 $ 3.2 $ 17.2 $ 10.9 $ 41.6 $ 34.9 $ 109.8 $ 0.3 $ 1.9 $ 2.6 $ 11.8 $ 28.3 $ 150.0 $ 94.9 $ 363.2 $ 305.0 $ 958.1 $

2013 0.0 $ 0.2 $ 0.3 $ 1.5 $ 3.6 $ 17.2 $ 10.9 $ 41.6 $ 34.9 $ 110.2 $ 0.3 $ 2.1 $ 2.8 $ 13.1 $ 31.4 $ 149.9 $ 94.8 $ 362.8 $ 304.6 $ 962.0 $

2014 0.0 $ 0.3 $ 0.4 $ 1.6 $ 3.9 $ 16.8 $ 10.7 $ 40.8 $ 34.2 $ 108.7 $ 0.3 $ 2.3 $ 3.1 $ 14.3 $ 34.2 $ 147.0 $ 93.0 $ 355.9 $ 298.8 $ 949.0 $

2015 0.0 $ 0.3 $ 0.4 $ 1.6 $ 3.9 $ 16.4 $ 10.3 $ 39.6 $ 33.3 $ 105.8 $ 0.3 $ 2.3 $ 3.1 $ 14.4 $ 34.5 $ 142.8 $ 90.3 $ 345.6 $ 290.2 $ 923.6 $

2016 0.0 $ 0.3 $ 0.4 $ 1.6 $ 3.9 $ 15.8 $ 10.0 $ 38.2 $ 32.1 $ 102.2 $ 0.3 $ 2.3 $ 3.1 $ 14.2 $ 33.9 $ 137.8 $ 87.1 $ 333.5 $ 280.0 $ 892.2 $

2017 0.0 $ 0.3 $ 0.3 $ 1.6 $ 3.8 $ 15.2 $ 9.6 $ 36.7 $ 30.8 $ 98.3 $ 0.3 $ 2.2 $ 3.0 $ 13.8 $ 33.0 $ 132.3 $ 83.7 $ 320.4 $ 269.0 $ 857.8 $

2018 0.0 $ 0.2 $ 0.3 $ 1.5 $ 3.6 $ 14.5 $ 9.2 $ 35.2 $ 29.5 $ 94.2 $ 0.3 $ 2.2 $ 2.9 $ 13.3 $ 31.8 $ 126.8 $ 80.2 $ 306.9 $ 257.7 $ 822.0 $

2019 0.0 $ 0.2 $ 0.3 $ 1.5 $ 3.5 $ 13.9 $ 8.8 $ 33.6 $ 28.2 $ 90.0 $ 0.3 $ 2.1 $ 2.8 $ 12.8 $ 30.6 $ 121.1 $ 76.6 $ 293.3 $ 246.2 $ 785.7 $

2020 0.0 $ 0.2 $ 0.3 $ 1.4 $ 3.4 $ 13.2 $ 8.4 $ 32.1 $ 26.9 $ 85.9 $ 0.3 $ 2.0 $ 2.7 $ 12.2 $ 29.3 $ 115.6 $ 73.1 $ 279.8 $ 234.9 $ 749.7 $

2021 0.0 $ 0.2 $ 0.3 $ 1.3 $ 3.2 $ 12.6 $ 8.0 $ 30.5 $ 25.6 $ 81.9 $ 0.3 $ 1.9 $ 2.5 $ 11.7 $ 28.0 $ 110.1 $ 69.6 $ 266.5 $ 223.8 $ 714.4 $

2022 0.0 $ 0.2 $ 0.3 $ 1.3 $ 3.1 $ 12.0 $ 7.6 $ 29.1 $ 24.4 $ 77.9 $ 0.3 $ 1.8 $ 2.4 $ 11.1 $ 26.7 $ 104.8 $ 66.3 $ 253.6 $ 212.9 $ 679.9 $

2023 0.0 $ 0.2 $ 0.3 $ 1.2 $ 2.9 $ 11.4 $ 7.2 $ 27.6 $ 23.2 $ 74.1 $ 0.3 $ 1.7 $ 2.3 $ 10.6 $ 25.4 $ 99.6 $ 63.0 $ 241.1 $ 202.4 $ 646.4 $

2024 0.0 $ 0.2 $ 0.3 $ 1.2 $ 2.8 $ 10.8 $ 6.9 $ 26.2 $ 22.0 $ 70.4 $ 0.2 $ 1.6 $ 2.2 $ 10.1 $ 24.2 $ 94.6 $ 59.8 $ 229.0 $ 192.3 $ 614.1 $

2025 0.0 $ 0.2 $ 0.2 $ 1.1 $ 2.6 $ 10.3 $ 6.5 $ 24.9 $ 20.9 $ 66.8 $ 0.2 $ 1.6 $ 2.1 $ 9.6 $ 23.0 $ 89.8 $ 56.8 $ 217.4 $ 182.6 $ 583.1 $

2026 0.0 $ 0.2 $ 0.2 $ 1.0 $ 2.5 $ 9.8 $ 6.2 $ 23.6 $ 19.8 $ 63.4 $ 0.2 $ 1.5 $ 2.0 $ 9.1 $ 21.8 $ 85.2 $ 53.9 $ 206.3 $ 173.2 $ 553.3 $

2027 0.0 $ 0.2 $ 0.2 $ 1.0 $ 2.4 $ 9.3 $ 5.9 $ 22.4 $ 18.8 $ 60.1 $ 0.2 $ 1.4 $ 1.9 $ 8.6 $ 20.7 $ 80.8 $ 51.1 $ 195.7 $ 164.3 $ 524.7 $

Total 0.6 $ 4.2 $ 5.6 $ 26.0 $ 62.3 $ 274.1 $ 173.4 $ 663.7 $ 557.2 $ 1,767.2 $ 5.4 $ 37.0 $ 49.2 $ 226.9 $ 543.5 $ 2,392.4 $ 1,513.3 $ 5,791.9 $ 4,863.3 $ 15,422.9 $

Ann. 0.1 $ 0.4 $ 0.5 $ 2.2 $ 5.3 $ 23.5 $ 14.9 $ 56.9 $ 47.8 $ 151.6 $ 0.5 $ 3.2 $ 4.2 $ 19.5 $ 46.6 $ 205.3 $ 129.9 $ 497.0 $ 417.3 $ 1,323.4 $

Notes:

Source: Derived from Exhibits F. 17a and F. 17b. Present values in millions of 2000 dollars. Estimates are discounted to 2003.

Detail may not add exactly to totals due to independent rounding. 2% Estimate of PAR Exhibit F. 17g Mean Present Value of Benefits Yearly Projections, WTP for Bronchitis as Basis for Non Fatal Cases, at 7% Discount Rate, by System Size ( All Systems)

17% Estimate of PAR Ann. = value of total annualized at discount rate.

Economic Analysis for the Stage 2 DBPR July 2003 1 Note: The Savitz et al. 1995 study had a response rate of 62 percent for miscarriage cases which is not unexpected due to the highly sensitive nature of this event.

Economic Analysis for the Stage 2 DBPR Proposal G 1 July 2003 Appendix G Illustrative Calculation for Quantifying Reproductive/ Developmental Benefits of the Stage 2 DBPR G. 1 Introduction and Purpose The purpose of this Appendix is to support Section 5.9.1 by providing details for an illustrative calculation that quantifies the benefits of reduced fetal losses ( miscarriage and stillbirth) potentially attributable to the reduction in elevated DBP levels from the Stage 2 DBPR. Fetal loss was chosen from among the reported reproductive and developmental health endpoints ( including neural tube defects, low birth weight, cardiovascular effects, intrauterine growth retardation and cleft palate, etc.) because there are relatively more epidemiological data for it in comparison to the other endpoints. In addition, fetal loss occurs at a high incidence rate in the US; of the approximately six million pregnancies experienced in the US each year, approximately one million end as fetal losses ( Ventura et al. 2000a). Consequently, even a small risk attributable to DBPs ( e. g., 0.1 percent) may result in a large number of fetal losses ( n= 1,000) and, thus, increase potential benefits from avoided cases of fetal losses for the Stage 2 DBPR.

Section G. 2 describes the derivation of PAR values relating fetal losses to DBP exposure. Section G. 3 presents the calculation of fetal losses avoided as a result of the Stage 2 DBPR. Assumptions and uncertainties in these calculations are summarized in Section G. 4.

G. 2 Derivation of PARs from Three Studies Fetal losses potentially attributable to DBPs in drinking water were estimated use the PAR approach, similar to the approach used to quantify benefits associated with reduced incidence of bladder cancer cases in the main benefits analysis. PAR is a measure of the fraction of a disease that occurs in the population that is attributable to some specified risk factor. By extension, it also implies the fraction of that disease that would be eliminated from the population if the specified risk factor was eliminated.

To derive PAR, EPA evaluated three separate, published population based human epidemiology studies:

° Waller et al. 2001 ° King et al. 2000a ° Savitz et al. 1995 Exhibit G. 1 summarizes the key characteristics of these studies. All three are considered high quality studies as they conform to the following criteria: 1) population based case control or cohort study that ascertained exposure to chlorinated surface water, 2) high quality, well designed study that had sufficient sample sizes, high response rates1, and adjusted for known confounding factors, and 3) exposure assessment using information from water treatment data, residential histories, and THM measurement Economic Analysis for the Stage 2 DBPR Proposal G 2 July 2003 % PAR = 100% * Pc * ( RR 1) / RR % PAR = 100% * Pe*( RR 1) / [( Pe*( RR 1)) + 1] data. These are the same criteria used to select the bladder cancer studies for the primary benefits analysis for both Stage 1 and Stage 2 DBPR.

Exhibit G. 1 Summary of the Fetal Loss Human Epidemiology Studies Study Type of Study and Population Exposure Assessment Outcome Potential Confounders Waller et al. 2001 Prospective cohort of 4,209 pregnant women in prepaid health plan in CA 1989 91 Averaged all distribution TTHM measurements taken within the subjects first trimester or average measurements taken within 30 days of first trimester. Spontaneous abortion ( # 20 weeks of gestation) Gestational age at interview, maternal age, cigarette smoking, history of pregnancy loss, maternal race, employment during pregnancy King et al. 2000a Population based retrospective cohort of 47,275 births in Nova Scotia, Canada 1988 1995 Linked mother's residence at time of delivery to the levels of specific TTHMs monitored in the PWS and averaged predicted values of byproduct level for the months covering the pregnancy Stillbirth Smoking, maternal age Savitz et al. 1995 Population based case control study of 126 cases and 122 controls in NC 1988 91 Fourth week of pregnancy used to assign the reported quarterly average TTHM Spontaneous abortion Maternal age, race, education, marital status, poverty level, smoking, alcohol use, nausea, employment The PARs were derived using the risk estimates ( Odds Ratios or Relative Risks) from the three studies. To determine the fraction of cases within the exposed population that would be attributable to a specific exposure ( i. e., PAR value), the proportion of exposed cases can be derived from either the study population or national occurrence information. To calculate a PAR value using the study exposed fraction, Formula # 1 would be used. Formula # 2, which is mathematically equivalent to Formula # 1, would be used when adjusting the exposed fraction using the national occurrence data.

Formula # 1 RR= Relative Risk or Odds Ratio Pc= the prevalence of exposure in the cases ( total number of exposed cases/ total number of cases)

Formula # 2 RR = Relative Risk or Odds Ratio Pe = fraction of the exposed population Economic Analysis for the Stage 2 DBPR Proposal G 3 July 2003 It is common practice to use the study population derived exposed fraction of cases to calculate the PAR estimate ( Formula # 1) by making the assumption that the study populations is representative of the general U. S. population. However, analysis of ICR occurrence data show that study populations have higher DBP exposures than the general U. S. population. National DBP exposure is compared to study population exposure in Section G. 2.1. Section G. 2.2 follows with detailed derivation of PAR using Formula # 2 ( adjusted to be more representative of national exposure levels).

G. 2.1 DBP Exposure for Study Populations Compared to National Data Section 5.4.1 provides a basis for why ICR data can be used to represent national exposure to DBPs. Below is a discussion of how EPA compared ICR data to the exposure characterizations of three epidemiology studies. The data are presented in a different manner than in <IP_ADDRESS> to reflect the specific methodologies used in the epidemiology studies to characterize exposure.

Summary of exposure characterizations from epidemiological studies The three epidemiological studies used in this analysis differ in geographic location, health endpoints, study type, and exposure classification. Major features of the studies are summarized in Exhibit G. 1. The three studies assigned pregnancies to multiple exposure categories, but the categorizations most closely related to the Stage 2 DBP MCL are those closest to the MCL ( 80 m g/ L). Exhibits G. 2 and G. 3 presents the study data that are used to assess representativeness of national exposure in this appendix.

Exhibit G. 2 DBP Exposure Data for Cohort Studies ( Waller et al. 2001 and King et al. 2000a)

Study Exposure Cases Non Cases Total Percent of Population Waller et al. 2001, Table 2 1st Trimester Mean TTHM > 80 74 578 652 15.5% 1 1st Trimester Mean TTHM < 80 322 3,238 3,560 84.5%

King et al. 2000a, Table 3 Pregnancy Mean TTHM > 75 m g/ L 75 15,163 15,238 32.4% 2 Pregnancy Mean TTHM < 75 m g/ L 122 31,718 31,840 67.5%

Notes: 1. As derived from original study data: ( 488+ 164)/( 488+ 164+ 488+ 1139+ 715+ 654+ 564) = 652/( 652+ 3650) = 15.5% 2. As derived from original study data: ( 31+ 44+ 7350+ 7813)/( 31+ 44+ 7350+ 7813+ 43+ 79+ 12987+ 18730)= 15,258/( 15,258+ 31,840)= 32.4% Economic Analysis for the Stage 2 DBPR Proposal G 4 July 2003 Exhibit G. 3 DBP Exposure Data for Case Control Study ( Savitz et al. 1995, Table 2)

Exposure Cases Controls Percent of Population 1 1st Trimester Mean TTHM > 81 m g/ L 46 43 35.2% 2 1st Trimester Mean TTHM < 81 m g/ L 80 79 64.8%

TOTAL 126 122 Notes 1. For case control studies, the distribution of population exposure is most appropriately represented by the control group only. 2. 43/( 43+ 79) = 35.2%

Comparison of exposure between ICR data and study populations EPA derived national exposure estimates based on the ICR data using the exposure study definitions by Waller et al. 2001, Savitz et al. 1995, and King et al. 2000a. For the Waller study, EPA used the first trimester utility wide average, rather than the closest site estimate, as only this definition could be applied to the ICR data. This assumption is supported by the Waller et al. 2001 comment that there is little difference between the exposure estimates derived from the utility wide average versus the closest site estimates. In analyzing the ICR data for purpose of exposure comparison with the Waller study, EPA considered the plants having data from at least 3 distribution system locations with at least three valid results for both TTHM and HAA5 during the final year of the ICR survey, i. e., ICR quarters 3, 4, 5, and 6. Among these plants, 77 out of 1,130 plant quarters ( 6.8 percent) had distribution system averages greater than 80 m g/ L, and therefore are categorized as high exposure per Waller. The Savitz study also used utility wide averages in a given quarter as the basis for the exposure estimates. Thus, the 6.8 percent exposure estimate from the ICR data for Savitz is essentially the same as for Waller since the population cutoffs are only different by 1 m g/ L, i. e., 80 vs 81 m g/ L.

For the King study, exposure was estimated by averaging predicted TTHM values for the months covering the duration of the mother's pregnancy and using 75 m g/ L as the exposure concentration for comparisons. To relate the King exposure estimate to the ICR data, EPA calculated locational nine month running averages from the ICR data; i. e., locational averages for 3 consecutive quarters. Each ICR plant location provided three or four nine month averages, taking quarters ( 3,4,5), ( 3,4,6), ( 3,5,6), or ( 4,5,6). Of the 4,917 location nine month averages from the ICR data, 314 ( 6.4%) exceeded 75 m g/ L, and therefore are categorized as high exposure per King.

Exhibit G. 4 compares DBP exposures for the studies and ICR data using the study exposure definitions. The fraction of cases among the study population experiencing TTHM occurrences over 80 µ g/ L ( current TTHM MCL) is 15 percent to 35 percent. National ICR DBP occurrence data indicate that approximately 6.8 percent of the U. S. population are potentially exposed to TTHM levels higher than the current MCL of 80 µ g/ L during any of the four quarters during the last 12 months of the ICR. Economic Analysis for the Stage 2 DBPR Proposal G 5 July 2003 Exhibit G. 4: Comparison of DBP Peak Exposures: Fractions Exposed in Study and ICR Populations Data Source Waller et al. ( 1st trimester > 80) Savitz et al. ( 1st trimester > 81) King et al. ( pregnancy mean > 75) Study Population 15% 35% 32%

ICR Population 6.8% 6.8% 6.4%

Note: The King et al. estimate is based on running average values over nine months whereas the Waller et al. and Savitz et al. studies are based on averages for three month periods ( quarters) and thus, would include systems that exceeded the threshold for one three month period over nine months.

G. 2.2 PAR Results Using OR or RR and Scaling to National Exposure PAR estimates were derived using risk estimates and odds ratios calculated from the studies ( summarized in Exhibit G. 5). Each study assigned pregnancies to multiple exposure categories, but the exposure category closest to the Stage 2 DBP TTHM MCL ( 80 µ g/ L) was used to recalculate OR/ RR. For the Waller et al. 2001 and Savitz et al. 1995 studies, persons with exposure to greater than or equal to 80 µ g/ L and 81   µ g/ L, respectively, were defined as " exposed." For the King et al. study, the cut off was established at 75 µ g/ L. In addition, to make the results from the Waller et. al. 2001 study comparable to the other studies, the utility wide, unweighted average TTHM concentrations were used, disregarding the number of glasses of water consumed per day. For this analysis, crude odds ratios were used because it was not possible to calculate adjusted odds ratios for the referent unexposed group with the limited information provided in the underlying studies. Hence, not all confounding variables have been considered.

PAR results were derived using Formula # 2, i. e., adjusting the exposed fraction in the study population to reflect national exposure levels. Note that the lower 95 percent confidence bound, which are calculated to be less than zero for all studies, were truncated to zero to reflect biological plausibility.

Exhibit G. 5 RR's, OR's and PAR Estimates for Three Epidemiological Studies Study Calculated RR and OR's 1 PAR Estimates 2 Median 95% Confidence Interval Median 95% Confidence Interval 3 Waller et al. 2001 RR = 1.25 0.99  1.6 1.7 % 0  4%

Savitz et al. 1995 OR = 1.06 0.6  1.8 0.4 % 0  4%

King et al. 2000a RR = 1.28 0.98  1.7 1.7 % 0  4%

Notes: 1. Re calculated by EPA for exposure levels as described in Section 2.2.1 using crude odds ratios reported in the studies 2. Based on Formula # 2: % PAR = 100% * ( Pe)* ( RR 1) / [( RR 1)* Pe + 1] where Pe is the fraction of the exposed population and RR is Relative Risks or Odds Ratio 3. Lower confidence bounds were truncated to zero to reflect biological plausibility Economic Analysis for the Stage 2 DBPR Proposal G 6 July 2003 G. 3 Estimate of Annual Fetal Losses Avoided as a Result of the Stage 2 DBPR All three epidemiology studies covered exposure periods that occurred between 1988 and 1995, before implementation of the Stage 1 DBPR. To calculate the number of fetal losses avoided as a consequence of the Stage 2 DBPR, TTHM quarterly distribution system data collected during the ICR were used to estimate the fraction of locations with peak exposures for pre Stage 1, pre Stage 2 ( post Stage 1), and post Stage 2 scenarios. From these fractions, the percent reduction in peak exposures attributed to the Stage 2 DBPR can be calculated ( See section 5.4.1 and Exhibit 5.13 for a discussion of this analysis). Although EPA recognizes that the developmental and reproductive health data described in section 5.2 does not conclusively identify the peak level of concern, a peak TTHM concentration of 80 : g/ L was assumed for all analyses, since this was closest to the level evaluated in the studies.

EPA made several assumptions for this analysis. For example, each ICR plant location ( DSE, AVG1, AVG2, and DS Maximum) was assumed to represent an equal portion of the population. Also, TTHM occurrence for ICR plants evaluated are assumed to represent national occurrence. Section G. 4 provides a full discussion of the assumptions and uncertainties for the derivation of fetal losses avoided as a result of the Stage 2 DBPR EPA estimates that approximately 1,100 to 4,700 fetal losses could be avoided per year as a result of the Stage 2 DBPR based on PAR values of 0.4 and 1.7 percent, respectively. The following four steps show the derivation of fetal losses avoided as a result of the Stage 2 DBPR for a PAR value of 1.7 percent. The same steps can be used to derive the results for the PAR value of 0.4 percent.

Step 1: Estimate the baseline number of fetal losses ( pre Stage 1 conditions) attributable to exposure to peak DBPs by multiplying the PAR value by the total number of fetal losses per year ( 983,000 from Ventura et al. 2000a).

1.7% PAR x 983,000 = 16,711 Exhibit G. 6 shows the range of baseline fetal losses attributable to DBPs for PAR values of 0 to 4 percent ( 95 confidence bounds based on the three studies).

Step 2: Estimate the percent of population exposed to peaks for Pre Stage 1, Pre Stage 2 and Post Stage 2 conditions ( source: derived in section <IP_ADDRESS>). Results for a TTHM study level of 80 : g/ L are shown in Exhibit G. 6.

Step 3: Estimate the fetal losses remaining for Pre Stage 2 conditions. First, estimate the fetal losses avoided by the Stage 1 DBPR by multiplying the Pre Stage 1 cases by the percent reduction in peak DBP exposure as a result of the Stage 1 DBPR ( shown in Exhibit G. 7)

16,911 x ([ 17.5%  7.1%]/ 17.5%) = 10,050 Subtract the fetal losses avoided as a result of the Stage 1 DBPR from the pre Stage 1 baseline number of fetal losses attributable to DBPs to produce the fetal losses remaining that are attributable to DBPs for Pre Stage 2 conditions 16,911  10,050 = 6,861 Economic Analysis for the Stage 2 DBPR Proposal G 7 July 2003 Step 4: Calculate the fetal losses avoided as a result of the Stage 2 DBPR. Similarly to Step 3, multiply the fetal losses remaining after the Stage 1 DBPR by the percent reduction in peak DBP exposure as a result of the Stage 1 DBPR ( shown in Exhibit G. 7)

6,861 x ([ 7.1%  2.2%]/ 7.1%] = 4,735 Economic Analysis for the Stage 2 DBPR Proposal G 8 July 2003 0 5,000 10,000 15,000 20,000 25,000 30,000 35,000 40,000 0.0% 0.5% 1.0% 1.5% 2.0% 2.5% 3.0% 3.5% 4.0%

PAR (%) Fetal Losses Attributable to DBPs Exhibit G. 6 Exposure to Peaks Based on ICR Data, TTHM Study Level of 80 : g/ L Pre Stage 1 Pre Stage 2 ( Post Stage 1) Post Stage 2 Locations with Peaks / Total Locations 215 / 1230 73 / 1035 19 / 880 Prevalence of Exposure ( Locations with Peaks / Locations) 17.5% 7.1% 2.2%

Source: Exhibit 5.13 Exhibit G. 7 Baseline Annual Fetal Losses Attributable to DBPs Based on Different PAR Values Economic Analysis for the Stage 2 DBPR Proposal G 9 July 2003 G. 4 Summary of Assumptions and Uncertainties There are a number of uncertainties and assumptions associated with calculating PAR and deriving the estimate of Fetal Losses that could be attributable to DBP exposure. The assumptions are necessary, however, for predicting exposure changes given the limited data on DBP occurrence in small systems and in distribution systems in general. These include:

° DBPs may not be the causative agent for these fetal losses.

° All confounding factors may not have been considered in these three studies.

° By using the crude odds ratios to recalculate the risk estimates, the PAR estimates may not have captured the true risk estimate.

° The total incidence for all fetal losses ( n= 983,000) was used to represent both spontaneous abortion and stillbirth because there is insufficient data to distinguish the number of miscarriages vs. number of stillbirths per year.

These assumptions and uncertainties are not all specific to this analysis; they would be true for many environmental epidemiology studies and population attributable risk calculations.

There are other uncertainties and assumptions associated with calculating the reduction in fetal losses that could be attributable to the Stage 2 DBPR. To translate DBP occurrence to DBP exposure, two assumptions were used.

° Each plant location ( DSE, AVG1, AVG2, and DS Maximum) represents an equal portion ( 25 percent) of the total population served by the plant.

° Peak DBP occurrence for 311 large ICR plants evaluated is representative of the peak DBP occurrence for all plants ( large and small).

Section <IP_ADDRESS> provides an assessment of the validity and impact of these assumptions.

Because DBP concentrations are highly variable in distribution systems, it is possible that the exposure analysis in Section <IP_ADDRESS> does not capture true variability in exposure to peaks. Uncertainties with interpretation of ICR data for the purposes of this exposure assessment include:

° The extent to which small system occurrence is represented ° Year to year variability of DBP occurrence data that might be affected by changes in source water quality ( e. g., drought years versus non drought years)

° The extent to which each ICR sampling point represents an equal fraction of the population served ° The extent to which ICR sampling locations represent compliance monitoring locations when trying to estimate reductions in exposure resulting from compliance with Stage 1 and Stage 2 DBPRs.


[Federal Register: March 23, 2009 (Volume 74, Number 54)]
[Rules and Regulations]
[Page 12086-12087]
[DOCID:fr23mr09-7]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. FAA-2008-0224; Directorate Identifier 2007-NE-44-AD;
Amendment 39-15860; AD 2009-07-01]
RIN 2120-AA64

Airworthiness Directives; Rolls-Royce Deutschland Ltd & Co KG
(RRD) BR700-715A1-30, BR700-715B1-30, and BR700-715C1-30 Turbofan
Engines

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: We are adopting a new airworthiness directive (AD) for the
products listed above. This AD results from mandatory continuing
airworthiness information (MCAI) issued by an aviation authority of
another country to identify and correct an unsafe condition on an
aviation product. The MCAI describes the unsafe condition as:

    It is necessary to change the limits of the High Pressure (HP)
Turbine Stage 1 and Stage 2 Rotor Discs. The maximum approved life
of these discs is decreased for all flight missions.
    This Emergency Airworthiness Directive (EAD) has been raised to
instruct mandatory decreased maximum approved lives in the BR715
Time Limits Manual (TLM) T-715-3BR for the HP Turbine Stage 1 Rotor
Disc for both Part No. BRH20130 and Part No. BRH20131 and of the
High Pressure (HP) Turbine Stage 2 Rotor Disc for both Part No.
BRH19423 and Part No. BRH19427 for all flight missions. The life
limits are decreased by the same proportion for all flight missions,
thus back to birth pro-rata calculations due to the life limit
changes are not necessary.

We are issuing this AD to prevent rotating parts that may have exceeded
their low-cycle fatigue life limits from failing, which could result in
uncontained engine failure and subsequent damage to the airplane.

DATES: This AD becomes effective April 27, 2009.

ADDRESSES: The Docket Operations office is located at Docket Management
Facility, U.S. Department of Transportation, 1200 New Jersey Avenue
SE., West Building Ground Floor, Room W12-140, Washington, DC 20590-
0001.

FOR FURTHER INFORMATION CONTACT: Jason Yang, Aerospace Engineer, Engine
Certification Office, FAA, Engine and Propeller Directorate, 12 New
England Executive Park, Burlington, MA 01803; e-mail:
<EMAIL_ADDRESS>telephone<PHONE_NUMBER>; fax<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

Discussion

    We issued a notice of proposed rulemaking (NPRM) to amend 14 CFR
part 39 to include an AD that would apply to the specified products.
That NPRM was published in the Federal Register on April 3, 2008 (73 FR
18220). That NPRM proposed to correct an unsafe condition for the
specified products. The MCAI states that:

    It is necessary to change the limits of the High Pressure (HP)
Turbine Stage 1 and Stage 2 Rotor Discs. The maximum approved life
of these discs is decreased for all flight missions.
    This Emergency Airworthiness Directive (EAD) has been raised to
instruct mandatory decreased maximum approved lives in the BR715
Time Limits Manual (TLM) T-715-3BR for the HP Turbine Stage 1 Rotor
Disc for both Part No. BRH20130 and Part No. BRH20131 and of the
High Pressure (HP) Turbine Stage 2 Rotor Disc for both Part No.
BRH19423 and Part No. BRH19427 for all flight missions. The life
limits are decreased by the same proportion for all flight missions,
thus back to birth pro-rata calculations due to the life limit
changes are not necessary.

Comments

    We gave the public the opportunity to participate in developing
this AD. We considered the comment received.

Correction to Table

    One commenter, Rolls-Royce Deutschland Ltd & Co KG, states that in
the 2nd table following paragraph (e)(1), in the lower half, fifth
column, ``1165'' should be corrected to read ``21165''.
    We agree and made the correction in the AD.

Change to Table Headings

    Since we issued the proposed AD, we determined that the headings in
the tables following paragraph (e)(1), of ``Mandatory Decreased Maximum
Approved Life'' are not sufficiently clear. We changed those headings
to ``Declared Safe Cyclic Life, in Flight Cycles'', in the AD.

Conclusion

    We reviewed the available data, including the comment received, and
determined that air safety and the public interest require adopting the
AD with the changes described previously. We determined that these
changes will not increase the economic burden on any operator or
increase the scope of the AD.

Cost of Compliance

    We estimate that this AD will affect 260 engines installed on
airplanes of U.S. registry. We also estimate that it will take about
one work-hour per engine to perform the actions and that the average
labor rate is $80 per work-hour. Based on these figures, we estimate
the total cost of the AD to U.S. operators to be $20,800. Our cost
estimate is exclusive of possible warranty coverage.

Authority for This Rulemaking

    Title 49 of the United States Code specifies the FAA's authority to
issue rules on aviation safety. Subtitle I, section 106, describes the
authority of the FAA Administrator. ``Subtitle VII: Aviation
Programs,'' describes in more detail the scope of the Agency's
authority.
    We are issuing this rulemaking under the authority described in
``Subtitle VII, Part A, Subpart III, Section 44701: General
requirements.'' Under that section, Congress charges the FAA with
promoting safe flight of civil aircraft in air commerce by prescribing
regulations for practices, methods, and procedures the Administrator
finds necessary for safety in air commerce. This regulation is within
the scope of that authority because it addresses an unsafe condition
that is likely to exist or develop on products identified in this
rulemaking action.

Regulatory Findings

    We determined that this AD will not have federalism implications
under Executive Order 13132. This AD will not have a substantial direct
effect on the States, on the relationship between the national
government and the States, or on the distribution of power and
responsibilities among the various levels of government.
    For the reasons discussed above, I certify this AD:
    1. Is not a ``significant regulatory action'' under Executive Order
12866;
    2. Is not a ``significant rule'' under the DOT Regulatory Policies
and Procedures (44 FR 11034, February 26, 1979); and
    3. Will not have a significant economic impact, positive or
negative, on a substantial number of small entities under the criteria
of the Regulatory Flexibility Act.
    We prepared a regulatory evaluation of the estimated costs to
comply with this AD and placed it in the AD docket.

Examining the AD Docket

    You may examine the AD docket on the Internet at http://
www.regulations.gov; or in person at the Docket Operations office
between 9 a.m. and 5 p.m., Monday through Friday, except Federal
holidays. The AD docket contains this AD, the regulatory evaluation,
any comments received, and

other information. The street address for the Docket Operations office
(telephone<PHONE_NUMBER>) is provided in the ADDRESSES section.
Comments will be available in the AD docket shortly after receipt.

List of Subjects in 14 CFR Part 39

    Air transportation, Aircraft, Aviation safety, Safety.

Adoption of the Amendment

0
Accordingly, under the authority delegated to me by the Administrator,
the FAA amends 14 CFR part 39 as follows:

PART 39--AIRWORTHINESS DIRECTIVES

0
1. The authority citation for part 39 continues to read as follows:

    Authority: 49 U.S.C. 106(g), 40113, 44701.

Sec.  39.13  [Amended]

0
2. The FAA amends Sec.  39.13 by adding the following new AD:

2009-07-01 Rolls-Royce Deutschland Ltd & Co KG (formerly BMW Rolls-
Royce GmbH, formerly BMW Rolls-Royce Aero Engines): Amendment 39-
15860. Docket No. FAA-2008-0224; Directorate Identifier 2007-NE-44-
AD.

Effective Date

    (a) This airworthiness directive (AD) becomes effective April
27, 2009.

Affected ADs

    (b) None.

Applicability

    (c) This AD applies to Rolls-Royce Deutschland Ltd & Co KG (RRD)
BR700-715A1-30, BR700-715B1-30, and BR700-715C1-30 turbofan engines.
These engines are installed on, but not limited to, McDonnell
Douglas Model 717-200 airplanes.

Reason

    (d) It is necessary to change the limits of the High Pressure
(HP) Turbine Stage 1 and Stage 2 Rotor Discs. The maximum approved
life of these discs is decreased for all flight missions.
    This Emergency Airworthiness Directive (EAD) has been raised to
instruct mandatory decreased maximum approved lives in the BR715
Time Limits Manual (TLM) T-715-3BR for the HP Turbine Stage 1 Rotor
Disc for both Part No. BRH20130 and Part No. BRH20131 and of the
High Pressure (HP) Turbine Stage 2 Rotor Disc for both Part No.
BRH19423 and Part No. BRH19427 for all flight missions. The life
limits are decreased by the same proportion for all flight missions,
thus back to birth pro-rata calculations due to the life limit
changes are not necessary.
    We are issuing this AD to prevent rotating parts that may have
exceeded their low-cycle fatigue life limits from failing, which
could result in uncontained engine failure and subsequent damage to
the airplane.

Actions and Compliance

    (e) No later than 30 days after the effective date of this AD
the following mandatory actions need to be completed for each
individual BR700-715 HP Turbine Stage 1 Rotor Disc for both Part No.
BRH20130 and Part No. BRH20131 and High Pressure (HP) Turbine Stage
2 Rotor Disc for both Part No. BRH19423 and Part No. BRH19427
installed in a BR700-715A1-30, B1-30 or C1-30 engine:
    (1) Identify the mandatory decreased maximum approved life for
the HP Turbine Stage 1 and Stage 2 Rotor Discs listed in the tables
below:

----------------------------------------------------------------------------------------------------------------
 High Pressure (HP) Turbine Stage 1 Rotor Disc             Declared Safe Cyclic Life, in Flight Cycles
----------------------------------------------------------------------------------------------------------------
                                                      Engine Thrust Rating            Engine Flight Mission
                                               -----------------------------------------------------------------
                   Part No.                                                                              C1-30
                                                  A1-30      B1-30      C1-30      A1-30      C1-30     derated
                                                  Design     Design     Design    Hawaiian   Tropical   Tropical
----------------------------------------------------------------------------------------------------------------
BRH20130......................................      15971      13324      10500      17647       3794       7941
BRH20131......................................      15971      13324      10500      17647       3794       7941
----------------------------------------------------------------------------------------------------------------

----------------------------------------------------------------------------------------------------------------
 High Pressure (HP) Turbine Stage 2 Rotor Disc             Declared Safe Cyclic Life, in Flight Cycles
----------------------------------------------------------------------------------------------------------------
                                                      Engine Thrust Rating            Engine Flight Mission
                                               -----------------------------------------------------------------
                   Part No.                                                                              C1-30
                                                  A1-30      B1-30      C1-30      A1-30      C1-30     derated
                                                  Design     Design     Design    Hawaiian   Tropical   Tropical
----------------------------------------------------------------------------------------------------------------
BRH19423......................................      21165      17800      13372      21165      10893      13461
BRH19427......................................      21165      17800      13372      21165      10893      13461
----------------------------------------------------------------------------------------------------------------

    (2) Record the mandatory maximum approved life in the applicable
lifing documentation. It is mandatory to use the values given in the
two tables in step (e)(1) of this AD.

Alternative Methods of Compliance (AMOCs)

    (f) The Manager, Engine Certification Office, FAA, has the
authority to approve AMOCs for this AD, if requested using the
procedures found in 14 CFR 39.19.

Related Information

    (g) Refer to EASA Emergency Airworthiness Directive 2007-0152-E
(corrected), dated June 1, 2007, for related information.
    (h) Contact Jason Yang, Aerospace Engineer, Engine Certification
Office, FAA, Engine and Propeller Directorate, 12 New England
Executive Park, Burlington, MA 01803; e-mail<EMAIL_ADDRESS>
telephone<PHONE_NUMBER>; fax<PHONE_NUMBER>, for more information
about this AD.

Material Incorporated by Reference

    (i) None.

    Issued in Burlington, Massachusetts, on March 17, 2009.
Francis A. Favara,
Manager, Engine and Propeller Directorate, Aircraft Certification
Service.
 [FR Doc. E9-6226 Filed 3-20-09; 8:45 am]

BILLING CODE 4910-13-P